Document:

EXHIBIT 4.4

         

        

      

      SECOND SUPPLEMENTAL INDENTURE

       

      This Second Supplemental Indenture, made as of November 19, 2020 (the “Supplemental Indenture”), to that certain Indenture (as such indenture has been supplemented and amended by the First
        Supplemental Indenture, dated November 3, 2020 (the “First Supplemental Indenture”), the “Existing Indenture” and the Existing Indenture, as it may from time to time be supplemented or amended by one or more additional indentures
        supplemental thereto entered into pursuant to the applicable provisions thereof, being hereinafter called the “Indenture”) dated as of July 15, 2019 among Aquestive Therapeutics, Inc., a Delaware corporation with an address at 30 Technology
        Drive, Warren, New Jersey 07059 (the “Issuer”), any Guarantor that becomes party thereto pursuant to Section 4.10 of the Existing Indenture, and U.S. Bank National Association, as trustee (the “Trustee”) and as collateral agent (the “Collateral
          Agent”).

       

      WHEREAS, the Issuer has heretofore executed and delivered to the Trustee the Existing Indenture, providing for the issuance of an aggregate principal amount of up to $104.0 million of 12.5% Senior
        Secured Notes due 2025 (the “Notes”);

       

      WHEREAS, the Existing Indenture provides for certain exceptions to the Note repurchase requirements otherwise applicable to the Issuer in connection with the Issuer’s receipt of the initial cash
        amount of $40,000,000 pursuant to the sale by the Issuer of certain rights to receive royalties and milestone payments under its license agreement with Sunovion Pharmaceuticals Inc.;

       

      WHEREAS, the Issuer proposes to amend the Existing Indenture, the First Supplemental Indenture and the Notes (the “Proposed Amendments”), which amendments, pursuant to Section 9.02 of the
        Indenture, must be approved with the written consent of the Holders of all of the aggregate principal amount of the outstanding Notes (the “Required Holders”);

       

      WHEREAS, the Issuer has received and delivered to the Trustee and to the Collateral Agent the consent of the Required Holders to the Proposed Amendments (the “Holder Consent”);

       

      WHEREAS, the Issuer has been authorized by a resolution of its board of directors to enter into this Supplemental Indenture;

       

      WHEREAS, all other acts and proceedings required by law, by the Existing Indenture and by the certificate of incorporation and bylaws of the Issuer to make this Supplemental Indenture a valid and
        binding agreement for the purposes expressed herein, in accordance with its terms, have been duly done and performed;

       

      WHEREAS, pursuant to Section 9.02, the Trustee and the Collateral Agent are authorized to execute and deliver this Supplemental Indenture;

       

      WHEREAS, following the execution of this Supplemental Indenture, the terms hereof will become operative on the date hereof.

       

      NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH:

       

      
        
          

      

      
      That, for and in consideration of the premises herein contained and in order to effect the Proposed Amendments contained herein, pursuant to Section 9.02 of the Existing Indenture, the Issuer
        agrees with the Trustee and the Collateral Agent as follows:

       

      ARTICLE 1

        

        Amendment of Existing Indenture

       

      Section 1.01.         Amendment of Existing Indenture.  Effective as of the Supplement Effective Date, this Supplemental Indenture amends the Existing Indenture as provided for
        herein.

       

      Section 1.02.          Amendment of Section 1.01.  Pursuant to Section 9.02 of the Existing Indenture, Section 1.01 of the Existing Indenture is hereby amended:

       

      By amending and restating the definition of “2020 Additional Securities Issuance Date” in its entirety to read as follows:

       

      ““2020 Additional Securities Issuance Date” shall be November 19, 2020.”

       

      By amending and restating the definition of “Repurchase” in its entirety to read as follows:

       

      ““Repurchase” means the repurchase on November 19, 2020 of the $22,500,000 aggregate principal amount of Original Securities, for 100.000% of the principal amount thereof plus accrued and
        unpaid interest, if any, thereon to the date of repurchase, pursuant to the October 2020 Purchase Agreements.”

       

      By adding the following definitions:

       

      “”Permitted Apomorphine Monetization Agreement” means that certain Purchase and Sale Agreement, dated as of November 3, 2020, between the Issuer and MAM Pangolin Royalty, LLC.”

       

      ““Second Apomorphine Monetization Payment” means the cash amount of $10,000,000 that may be received by the Company pursuant to Section 2.2(b) of the Permitted Apomorphine Monetization Agreement.”

       

      Section 1.03.        Amendment of Section 4.06.  Pursuant to Section 9.02 of the Existing Indenture, Section 4.06 of the Existing Indenture shall be amended and restated in its entirety as
        follows:

       

      “Section 4.06.       Asset Sales.

       

      (a)          General.  The Issuer shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, (i) make a Disposition or (ii) issue or sell Equity
        Interests (other than directors’ qualifying shares and shares issued to foreign nationals or other third parties to the extent required by applicable law) of any Restricted Subsidiary (other than to the Issuer or another Restricted Subsidiary of
        the Issuer) (whether in a single transaction or a series of related transactions), in each case except for (A) the Permitted Apomorphine Monetization, and (B) Permitted Asset Sales.

      

      
        2

        
          

      

      (b)           Permitted Apomorphine Monetization.

       

      (i)        Upon the receipt of any cash proceeds by the Issuer from the Permitted Apomorphine Monetization (other than the Upfront Apomorphine Monetization Payment and Second
        Apomorphine Monetization Payment), each Holder shall have the right to require the Issuer to repurchase all or any part of such Holder’s then outstanding Securities at a repurchase price in cash equal to 112.5000% of the principal amount thereof,
        plus accrued and unpaid interest, if any, thereon to the repurchase date (subject to the right of the Holders of record on the relevant Record Date to receive interest due on the related Payment Date), in accordance with the terms contemplated in
        this Section 4.06(b); provided, however, that notwithstanding the occurrence of the Permitted Apomorphine Monetization, the Issuer shall not be obligated to
        repurchase any Securities pursuant to this Section 4.06(b) in the event that it has exercised (x) its unconditional right to redeem such Securities in accordance with Article 3 or (y) its legal defeasance option or covenant defeasance option in
        accordance with Article 8; (i) such repurchase offer shall be for 30% of the cash proceeds received by the Issuer in such Permitted Apomorphine Monetization (the “30% Limitation”), (ii) the Issuer
        shall not be obligated to repurchase Securities from any Holder with the proceeds of the Upfront Apomorphine Monetization Payment, except for the Repurchase, or the Second Apomorphine Monetization Payment; and (iii) that the Issuer shall not
        repurchase more than $40,000,000 in aggregate principal amount of Securities from the cash proceeds from the Permitted Apomorphine Monetization (or $50,000,000 in aggregate principal amount of Securities if the First Additional Securities have been
        issued) (and, in the event that the aggregate principal amount of Securities so requested to be repurchased pursuant to this Section 4.06(b) would otherwise exceed $40,000,000 (or $50,000,000 if the First Additional Securities have been issued),
        then the Issuer shall repurchase the Securities from such Holders on a pro rata basis); provided, such $40,000,000 (or $50,000,000 if the First Additional Securities have been issued) in aggregate principal amount of Securities to be repurchased
        with cash proceeds from the Permitted Apomorphine Monetization shall be reduced by the aggregate principal amount of Original Securities purchased by the Issuer in the Repurchase.

       

      (ii)      Within 30 days following the receipt of cash proceeds from the Permitted Apomorphine Monetization (other than the Upfront Apomorphine Monetization Payment and Second
        Apomorphine Monetization Payment), except to the extent that the Issuer has exercised (x) its unconditional right to redeem the Securities by delivery of a notice of redemption in accordance with Article 3 or (y) its legal defeasance option or
        covenant defeasance option in accordance with Article 8, the Issuer shall provide a written notice (an “Apomorphine Asset Sale Offer”) to each Holder with a copy to the Trustee stating:

       

      (A)          the Issuer has received cash proceeds from the Permitted Apomorphine Monetization and that such Holder has the right to require the Issuer to repurchase (subject to
        the second proviso of Section 4.06(b)(i)) all or any part of such Holder’s then outstanding Securities at a repurchase price in cash equal to 112.5000% of the principal amount thereof, plus accrued and unpaid interest, if any, thereon to the
        repurchase date (subject to the right of the Holders of record on the relevant Record Date to receive interest due on the related Payment Date), subject to the 30% Limitation;

       

      
        3

        
          

      

      (B)       the amount of cash proceeds received by the Issuer from such Permitted Apomorphine Monetization that triggered delivery of the Apomorphine Asset Sale Offer, including
        a calculation of the 30% Limitation;

       

      (C)        the aggregate amount of cash proceeds received by the Issuer in the Permitted Apomorphine Monetization, through the date of such Apomorphine Asset Sale Offer;

       

      (D)           the repurchase date (which shall be no earlier than 30 days nor later than 60 days from the date such written notice is provided); and

       

      (E)         the instructions determined by the Issuer, consistent with this Section 4.06(b), that a Holder must follow in order to have its Securities repurchased.

       

      (iii)         At any time prior to the Libervant Approval, to the extent that the aggregate principal amount of Securities repurchased by the Issuer pursuant to this
        Section 4.06(b), taken together with any prior repurchases by the Issuer pursuant to this Section 4.06(b) including the amounts repurchased in the Repurchase, is less than $40,000,000 (or $50,000,000 if the First Additional Securities have been
        issued),  the difference between (x) the cash proceeds received by the Issuer in the Permitted Apomorphine Monetization (excluding the Upfront Apomorphine Monetization Payment and the Second Apomorphine Monetization Payment) limited to the first
        $40,000,000 of all such cash proceeds (or $50,000,000 if the First Additional Securities have been issued) and (y) the aggregate principal amount of Securities so repurchased shall be deposited into the Collateral Account; provided, for the
        avoidance of doubt, all amounts received by the Issuer in the Upfront Apomorphine Monetization Payment and the Second Apomorphine Monetization Payment not used to repurchase Securities in the Repurchase shall be retained by the Issuer and shall not
        be deposited in the Collateral Account.

       

      (iv)        Holders electing to have a Security repurchased pursuant to this Section 4.06(b) shall be required to surrender the Security, with an appropriate form duly completed,
        to the Issuer at the address specified in the Apomorphine Asset Sale Offer (or otherwise in accordance with the applicable procedures of the Depository) at least three Business Days prior to the repurchase date.  The Holders shall be entitled to
        withdraw their election if the Issuer receives not later than one Business Day prior to the repurchase date a letter setting forth the name of the Holder, the principal amount of the Security that was delivered for repurchase by the Holder and a
        statement that such Holder is withdrawing its election to have such Security repurchased.  Holders whose Securities are repurchased only in part shall be issued new Securities equal in principal amount to the portion of the Securities surrendered
        but not repurchased.  If the Securities are Global Securities held by the Depository, then the applicable operational procedures of the Depository for tendering and withdrawing securities will apply.

       

      
        4

        
          

      

      (v)        On the repurchase date, all Securities repurchased by the Issuer under this Section 4.06(b) shall be delivered to the Trustee for cancellation, and the Issuer shall
        pay the repurchase price plus accrued and unpaid interest, if any, thereon to the date of repurchase, to the Holders entitled thereto.

       

      (vi)         Securities repurchased by the Issuer pursuant to this Section 4.06(b) will have the status of Securities issued but not outstanding or will be retired and canceled
        at the option of the Issuer.

       

      (vii)        At the time the Issuer delivers (or causes to be delivered) Securities to the Trustee that are to be accepted for repurchase, the Issuer shall also deliver an
        Officers’ Certificate stating that such Securities are to be accepted by the Issuer pursuant to and in accordance with the terms of this Section 4.06(b) and confirming whether the Securities will be considered issued but not outstanding or
        including orders to cancel the repurchased Securities.  A Security shall be deemed to have been accepted for repurchase at the time the Trustee, directly or through an agent, provides payment therefor to the surrendering Holder.

       

      (viii)      Prior to providing written notice to the Holders of any Apomorphine Asset Sale Offer pursuant to Section 4.06(b)(ii), the Issuer shall deliver to the Trustee an
        Officers’ Certificate stating that all conditions precedent contained herein to the right of the Issuer to make such offer have been complied with.

       

      (ix)       The Issuer shall comply, to the extent applicable, with the requirements of Section 14(e) of the Exchange Act and any other securities laws or regulations in
        connection with the repurchase of Securities pursuant to this Section 4.06(b).  To the extent that the provisions of any securities laws or regulations conflict with provisions of this Section 4.06(b), the Issuer shall comply with the applicable
        securities laws and regulations and shall not be deemed to have breached its obligations under this Section 4.06(b) by virtue thereof.

       

      (c)           Administration of Collateral Account.

       

      (i)           The Issuer shall establish and maintain a segregated account held with U.S. Bank National Association (or another segregated account in replacement thereof held
        with another U.S. federally insured depositary financial institution that is acting as the Trustee or other Paying Agent) in the name of the Trustee or other Paying Agent (acting in either case as an agent for or representative of the Collateral
        Agent), or in the name of the Issuer, in each case, subject to the Liens established under the Collateral Agreement and the other Security Documents (such account, the “Collateral Account”).  The Collateral Account shall be established and
        maintained so as to create, perfect and establish the priority of the Liens established under the Collateral Agreement and the other Security Documents in such Collateral Account and all funds and other assets or property from time to time
        deposited therein or credited thereto and otherwise to effectuate the Liens under the Security Documents.  The Collateral Account shall bear a designation clearly indicating that the funds and other assets or property deposited therein or credited
        thereto are held for the benefit of the Holders and the Trustee.

       

      
        5

        
          

      

      (ii)         The Trustee or other Paying Agent, as applicable, shall have sole dominion and control over the Collateral Account (including, among other things, the sole power to
        direct withdrawals or transfers from the Collateral Account).  The Trustee or other Paying Agent, as applicable, shall make withdrawals and transfers from the Collateral Account in accordance with the terms of this Indenture.  Each of the Issuer
        and the Trustee, any other Paying Agent and the Collateral Agent acknowledges and agrees that the Collateral Account is a “securities account” within the meaning of Section 8-501 of the Uniform Commercial Code and that the Trustee or other Paying
        Agent, as applicable, has “control”, for purposes of Section 9-314 of the Uniform Commercial Code, of the Collateral Account that is maintained with the Trustee or other Paying Agent.  The Trustee hereby confirms that it has established account
        number 217428010 in the name of the Issuer for the benefit of the Holders and the Trustee as the Collateral Account.  The Issuer and the Trustee, any other Paying Agent and the Collateral Agent further agree that the jurisdiction of the Trustee,
        such other Paying Agent or the Collateral Agent, as applicable, for purposes of the Uniform Commercial Code shall be the State of New York.  The crediting by the Trustee or other Paying Agent, as applicable, to the Collateral Account of any asset
        or property that is not otherwise a financial asset by virtue of Section 8-102(a)(9)(i) of the Uniform Commercial Code or Section 8-102(a)(9)(ii) of the Uniform Commercial Code, including cash, shall constitute the “express agreement” of the
        Trustee or such other Paying Agent, as applicable, under Section 8-102(a)(9)(iii) of the Uniform Commercial Code that such property is a financial asset under Section 8-102(a)(9)(iii) of the Uniform Commercial Code.

       

      (iii)       The funds in the Collateral Account shall be released to the Issuer in whole or in part (free and clear of any Liens established under the Collateral Agreement and
        any other applicable Security Document) only upon (A) the occurrence of the Second Additional Securities Triggering Event and receipt by the Trustee or other applicable Paying Agent of the Second Additional Securities Triggering Event Officers’
        Certificate or (B) the written consent of the Holders of a majority in principal amount of the Securities.  The funds in the Collateral Account may not otherwise be withdrawn except (x) upon the occurrence and during the continuance of an Event of
        Default at the direction of the Holders of a majority in principal amount of the Securities as further described in Article 6, (y) to the Issuer following the discharge of this Indenture or (z) solely to be used in connection with the Issuer’s (A)
        unconditional right to redeem the Securities in whole in accordance with Article 3 or (B) legal defeasance option or covenant defeasance option in accordance with Article 8.  Funds in the Collateral Account may be invested by the Trustee or such
        Paying Agent in Cash Equivalents available to the Trustee or other Paying Agent, as applicable, at the written direction of the Issuer absent the occurrence and continuance of an Event of Default.  Promptly following the occurrence of an Event of
        Default and during the continuation thereof, the Trustee or other Paying Agent, as applicable (acting as an agent for or representative of the Collateral Agent), shall direct the funds in the Collateral Account to be invested pursuant to the
        direction of the Holders of a majority in principal amount of the Securities that are available to the Trustee or other Paying Agent, as applicable.  In the absence of written instructions, no investments shall be made using the funds in the
        Collateral Account.

       

      
        6

        
          

      

      (iv)      The cash proceeds in respect of the Permitted Apomorphine Monetization in excess of the first $40,000,000 of cash proceeds from the Permitted Apomorphine Monetization
        (or $50,000,000 if the First Additional Securities have been issued) may be used by the Issuer for any purpose that is not prohibited by this Indenture.  At any time following the Second Additional Securities Triggering Event, after any repurchase
        of Securities by the Issuer pursuant to Section 4.06(b), any cash proceeds in respect of the Permitted Apomorphine Monetization not used for such repurchase may be used by the Issuer for any purpose that is not prohibited by this Indenture. 
        Notwithstanding anything to the contrary in this Indenture, all amounts received by the Issuer in the Upfront Apomorphine Monetization Payment not used to repurchase Securities in the Repurchase and the Second Apomorphine Monetization Payment shall
        be retained by the Issuer free and clear of this Section 4.06(c) and shall not be deposited in the Collateral Account.”

       

      ARTICLE 2

       

      Amendment to First Supplemental Indenture

       

      Effective as of the Supplement Effective Date, this Supplemental Indenture amends the First Supplemental Indenture as provided for herein:

       

      Section 2.01.         Amendment of Article 3.  Pursuant to Section 9.02 of the Existing Indenture, the lead in of Article 3 of the First Supplemental Indenture shall be amended and restated
        in its entirety as follows:

       

      “This Supplement shall be deemed to be effective on November 19, 2020, assuming each of the following conditions is satisfied as of such date (the “Supplemental Effective Date”):”

      

      

      ARTICLE 3

        

        Amendment to Notes

       

      Effective as of the Supplement Effective Date, this Supplemental Indenture amends the Notes as provided for herein:

       

      Section 3.01.          Amendment of Section 8.  Pursuant to Section 9.02 of the Existing Indenture and Section 15 of the Notes, Section 8 of the Notes shall be amended and restated in its
        entirety as follows:

       

      
        7

        
          

      

      “Upon the receipt of any cash proceeds by the Issuer in the Permitted Apomorphine Monetization
          (other than the Upfront Apomorphine Monetization Payment and the Second Apomorphine Monetization Payment), each Holder shall have the right, subject to certain conditions specified in the Indenture, to require the Issuer to repurchase all or any
          part of such Holder’s then outstanding Securities at a repurchase price in cash equal to 112.5000% of the principal amount thereof, plus accrued and unpaid interest, if any, thereon to the repurchase date (subject to the right of the Holders of
          record on the relevant Record Date to receive interest due on the related Payment Date), as provided in, and subject to the terms of, the Indenture.”

      

      

      ARTICLE 4

        

        Conditions Precedent

       

      This Supplement shall be deemed to be effective on November 19, 2020, assuming each of the following conditions is satisfied as of such date (the “Supplemental Effective Date”):

      

      

      Section 4.01.          Executed Supplement.  The Trustee and Collateral Agent shall have received from the Company and each Guarantor,
          counterparts of this Supplement signed on behalf of each of the parties hereto.

       

      Section 4.02.        Further Assurances.  The Collateral Agent and Trustee shall have received such documents as the Collateral Agent and Trustee or
          special counsel to the Collateral Agent and Trustee may reasonably request.

       

      Section 4.03.        Representatives and Warranties.  Each of the representations and warranties
          contained in the Purchase Agreements shall be true and correct in all material respects (except that any representation and warranty that is qualified as to “materiality” or “Material Adverse Effect” shall be true and correct in all respects) on
          and as of the Supplement Effective Date, except to the extent such representations and warranties expressly related to any earlier date.

       

      Section 4.04.          No Default.  No Default or Event of Default has occurred and is then continuing.

       

      ARTICLE 5

        

        Miscellaneous Provisions

       

      Section 5.01.         Ratification of Indenture; Supplemental Indentures Part of Indenture.  Except as expressly amended and supplemented hereby, the Indenture is in all respects ratified
        and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder shall be bound hereby.

       

      Section 5.02.         Defined Terms.  As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals hereto are used herein as therein defined, except
        that the term “Holders” in this Supplemental Indenture shall refer to the term “Holders” as defined in the Indenture and the Trustee and the Collateral Agent acting on behalf of and for the benefit of such Holders.  The words “herein”, “hereof” and
        “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

       

      
        8

        
          

      

      Section 5.03.        Counterparts.  The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy shall be an original, but all of them together
        represent the same agreement.  The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto
        and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

       

      Section 5.04.          Effect of Headings.  The Section headings herein are for convenience of reference only and shall not affect the construction thereof.

       

      Section 5.05.          Effectiveness.  The provisions of this Supplemental Indenture will take effect immediately upon execution thereof by the parties hereto.

       

      Section 5.06.          Governing Law.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF
        CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

       

      Section 5.07.          No Representation.  Neither the Trustee nor the Collateral Agent makes any representation as to the validity or sufficiency of this Supplemental Indenture.

       

      {Remainder of page intentionally left blank}

       

      
        9

        
          

      

      IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of the date first written above.

       

      
        	 	
                AQUESTIVE THERAPEUTICS, INC.

              
	 	 

        	
                 

              	By:	/s/ John T. Maxwell

              
	
                 

              	
                 

              	Name: John T. Maxwell

              
	
                 

              	
                 

              	Title: Senior Vice President – Chief Financial Officer

      

      
         

        

        Signature Page to the Second Supplemental Indenture

         

        

      

      
        
          

      

      
        	
                 

              	
                U.S. BANK NATIONAL ASSOCIATION,

                

              
	
                 

              	as Trustee
	
                 

              	
                 

              

        	
                 

              	By:	/s/ Allison D.B. Nadeau

              

        	
                 

              	
                 

              	Name: Allison D.B. Nadeau
	 	 	Title:   Vice President

      

      

      
        	
                 

              	
                U.S. BANK NATIONAL ASSOCIATION,

                

              
	
                 

              	as Collateral Agent
	
                 

              	
                 

              

      

      
        	
                 

              	By:	/s/ Allison D.B. Nadeau

              
	
                 

              	
                 

              	Name: Allison D.B. Nadeau

              
	
                 

              	
                 

              	Title:   Vice President

      

      

        Signature Page to the Second Supplemental IndentureExhibit 10.3

       

      PURCHASE AGREEMENT

       

      dated November 3, 2020

       

      between

       

      AQUESTIVE THERAPEUTICS, INC.

       

      and

       

      THE PURCHASER NAMED HEREIN

       

      $4,000,000 12.5% SENIOR SECURED NOTES DUE 2025

       

      and

       

      UP TO AN ADDITIONAL $10,000,000 12.5% SENIOR SECURED NOTES DUE 2025

       

      
        
          

      

      
      	
              Table of Contents

            
	  	
              Page

            
	
              ARTICLE I

            
	 INTRODUCTORY
	 
	
              Section 1.1

            	
              Introductory

            	
              1

              

            
	 	 	 
	
              ARTICLE II

            
	
              RULES OF CONSTRUCTION AND DEFINED TERMS

            
	 
	
              Section 2.1

            	
              Rules of Construction and Defined Terms

            	
              1

            
	 	 	 
	 	
              ARTICLE III

            	 
	 	
              SALE AND PURCHASE OF NOTES; CLOSING; FIRST ADDITIONAL SECURITIES AND WARRANTS

            	 
	 	 	 
	
              Section 3.1

            	
              Sale and Purchase of Notes; Closing

            	
              2

            
	
              Section 3.2

            	
              Repurchase of 2019 Notes

            	
              3

            
	 	 	 
	 	
              ARTICLE IV

            	 
	 	
              REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF PURCHASER

            	 
	 	 	 
	
              Section 4.1

            	
              Purchase for Investment and Restrictions on Resales

            	
              5

            
	
              Section 4.2

            	
              Purchaser Status

            	
              6

            
	
              Section 4.3

            	
              [Reserved]

            	
              6

            
	
              Section 4.4

            	
              Due Diligence

            	
              6

            
	
              Section 4.5

            	
              Enforceability of this Purchase Agreement

            	
              6

            
	
              Section 4.6

            	
              Tax Matters

            	
              7

            
	
              Section 4.7

            	
              Reliance for Opinions

            	
              7

            
	
              Section 4.8

            	
              2019 Notes

            	
              7

            

      

      

      
        i

        
          

      

      
      	 	
              ARTICLE V

            	 
	 	
              REPRESENTATIONS AND WARRANTIES OF THE ISSUER

            	 
	 	 	 
	
              Section 5.1

            	
              Securities Laws

            	
              7

            
	
              Section 5.2

            	
              Investment Company Act Matters

            	
              8

            
	
              Section 5.3

            	
              Apomorphine Purchase Agreement

            	
              8

            
	
              Section 5.4

            	
              Exchange Act Documents

            	
              8

            
	
              Section 5.5

            	
              Financial Statements

            	
              8

            
	
              Section 5.6

            	
              Organization; Power; Authorization; Enforceability

            	
              9

            
	
              Section 5.7

            	
              Organizational Information

            	
              9

            
	
              Section 5.8

            	
              Common Stock

            	
              9

            
	
              Section 5.9

            	
              [Reserved]

            	
              9

            
	
              Section 5.10

            	
              Governmental and Third Party Authorizations

            	
              10

              

            
	
              Section 5.11

            	
              No Conflicts

            	
              10

            
	
              Section 5.12

            	
              No Violation or Default

            	
              10

            
	
              Section 5.13

            	
              No Material Adverse Change

            	
              11

            
	
              Section 5.14

            	
              Compliance with ERISA

            	
              11

            
	
              Section 5.15

            	
              Tax Matters

            	
              11

            
	
              Section 5.16

            	
              Legal Proceedings

            	
              11

            
	
              Section 5.17

            	
              Solvency

            	
              12

            
	
              Section 5.18

            	
              Existing Indebtedness

            	
              12

            
	
              Section 5.19

            	
              Material Contracts

            	
              12

            
	
              Section 5.20

            	
              Properties

            	
              12

            
	
              Section 5.21

            	
              Intellectual Property

            	
              13

            
	
              Section 5.22

            	
              Environmental Matters

            	
              15

            
	
              Section 5.23

            	
              Labor Matters

            	
              15

            
	
              Section 5.24

            	
              Insurance

            	
              15

            
	
              Section 5.25

            	
              No Unlawful Payments

            	
              15

            
	
              Section 5.26

            	
              Compliance with Anti-Money Laundering Laws

            	
              16

            
	
              Section 5.27

            	
              Sanctions

            	
              16

            
	
              Section 5.28

            	
              Disclosure Controls

            	
              17

            
	
              Section 5.29

            	
              Accounting Controls

            	
              17

            
	
              Section 5.30

            	
              Licenses and Permits

            	
              17

            
	
              Section 5.31

            	
              Clinical Trials

            	
              18

            
	
              Section 5.32

            	
              Regulatory Filings

            	
              18

            
	
              Section 5.33

            	
              Compliance with Certain Regulatory Matters

            	
              19

            
	
              Section 5.34

            	
              Absence of Certain Regulatory Actions

            	
              19

            
	
              Section 5.35

            	
              Collateral Agreement

            	
              19

            

      

      

      	
              ARTICLE VI

            
	
              CONDITIONS TO CLOSING

            
	 
	
              Section 6.1

            	
              Issuer’s Counsel Opinion

            	
              20

            
	
              Section 6.2

            	
              Supplemental Indenture

            	
              20

            
	
              Section 6.3

            	
              Certification as to Purchase Agreement

            	
              20

            
	
              Section 6.4

            	
              Authorizations

            	
              20

            
	
              Section 6.5

            	
              [Reserved].

            	
              20

            
	
              Section 6.6

            	
              [Reserved]

            	
              20

            
	
              Section 6.7

            	
              Further Information

            	
              21

            
	
              Section 6.8

            	
              Consummation of Transactions

            	
              21

            
	
              Section 6.9

            	
              No Actions

            	
              21

            
	
              Section 6.10

            	
              Consents

            	
              21

            

      

      

      
        ii

        
          

      

      
      

      

      	
              ARTICLE VII

            
	 ADDITIONAL COVENANTS
	 
	
              Section 7.1

            	
              DTC

            	
              21

            
	
              Section 7.2

            	
              Expenses

            	
              21

            
	
              Section 7.3

            	
              Confidentiality; Public Announcement

            	
              21

            
	 	 	 
	
              ARTICLE VIII

            
	 SURVIVAL OF CERTAIN PROVISIONS
	 
	
              Section 8.1

            	
              Survival of Certain Provisions

            	
              22

            
	 
	
              ARTICLE IX

            
	 NOTICES
	 
	
              Section 9.1

            	
              Notices

            	
              23

            
	 	 	 
	
              ARTICLE X

            
	 SUCCESSORS AND ASSIGNS
	 
	
              Section 10.1

            	
              Successors and Assigns

            	
              23

            
	 	 	 
	
              ARTICLE XI

            
	 SEVERABILITY
	 
	
              Section 11.1

            	
              Severability

            	
              23

            
	 	 	 

      	
              ARTICLE XII

            
	 WAIVER OF JURY TRIAL
	 
	
              Section 12.1

            	
              WAIVER OF JURY TRIAL

            	
              23

            
	 	 	 
	
              ARTICLE XIII

            
	 GOVERNING LAW; CONSENT TO JURISDICTION
	 
	
              Section 13.1

            	
              Governing Law; Consent to Jurisdiction

            	
              23

            
	 	 	 
	
              ARTICLE XIV

            
	 COUNTERPARTS
	 
	
              Section 14.1

            	
              Counterparts

            	
              24

            
	 	 	 
	
              ARTICLE XV

            
	 TABLE OF CONTENTS AND HEADINGS
	 
	
              Section 15.1

            	
              Table of Contents and Headings

            	
              24

            

      

      

      
        iii

        
          

      

      	
              ARTICLE XVI

            
	 TAX DISCLOSURE
	 
	
              Section 16.1

            	
              Tax Disclosure

            	
              24

            
	 	 	 
	
              Annex A

            	
              Rules of Construction and Defined Terms

            	 
	
              Schedule 1

            	
              Purchaser

            	 
	
              Schedule 5.10

            	
              Governmental and Third Party Authorizations

            	 
	
              Schedule 5.21

            	
              Intellectual Property

            	 
	
              Schedule 5.30

            	Permits	
              

              

            
	 	 	 
	
              EXHIBIT A

            	Consent	
              

              

            
	
              EXHIBIT B

            	Supplemental Indenture	
              

              

            

      

      

      
        iv

        
          

      

      
      PURCHASE AGREEMENT

      November 3, 2020

       

      To the Purchaser named in Schedule 1

       

      Ladies and Gentlemen:

       

      Aquestive Therapeutics, Inc., a Delaware corporation (the “Issuer”), hereby covenants and agrees with you as follows:

       

      ARTICLE I

       

      INTRODUCTORY

       

      Section 1.1          Introductory.
        The Issuer proposes, subject to the terms and conditions stated herein, to issue to the purchaser named in Schedule 1 (the “Purchaser”) and to the Other Purchasers an additional $4,000,000 in aggregate principal amount of the Issuer’s 12.5% Senior Secured Notes due 2025, if applicable (the “November 2020 Notes”), up to an additional $10,000,000 in aggregate principal amount of the Issuer’s 12.5% Senior Secured Notes due 2025 (the “First Additional Notes”), and up to an aggregate principal amount equal to the difference of (x) $30,000,000 minus
        (y) the aggregate principal amount of any First Additional Notes actually issued, of the Issuer’s 12.5% Senior Secured Notes due 2025 (the “Second Additional Notes” and, together with the November 2020 Notes and the First Additional Notes,
        the “Notes”). The Issuer previously issued $70,000,000 aggregate principal amount of the 12.5% Senior Secured Notes due 2025 on July 15, 2019 (the “Existing Notes”). The principal amount of Notes to be issued to the Purchaser pursuant
        to this Purchase Agreement is set forth opposite the Purchaser’s name in Schedule 1. [The Closing Payment owing to each Purchaser pursuant to this Purchase Agreement is set forth opposite the Purchaser’s name in Schedule 1.]1
        The Notes to be issued to the Purchaser and the Other Purchasers, as applicable, are to be issued on the Applicable Closing Date (as defined below) pursuant to, and subject to the terms and conditions of, the Indenture.

       

      The Notes will be offered and sold to the Purchaser and the Other Purchasers (collectively, the “Purchasers”) in transactions exempt
        from the registration requirements of the Securities Act.

       

      ARTICLE II

       

      RULES OF CONSTRUCTION AND DEFINED TERMS

       

      Section 2.1            Rules
          of Construction and Defined Terms. The rules of construction set forth in Annex A shall apply to this Purchase Agreement and are hereby incorporated by reference into this Purchase Agreement as if set forth
        fully in this Purchase Agreement. Capitalized terms used but not otherwise defined in this Purchase Agreement shall have the respective meanings given to such terms in Annex A, which is hereby incorporated by reference into this Purchase
        Agreement as if set forth fully in this Purchase Agreement.

       

      
        

      1 Included in certain purchasers’ agreements.

       

      

      
        1

        
          

      

      ARTICLE III

       

      SALE AND PURCHASE OF NOTES; CLOSING; FIRST ADDITIONAL SECURITIES AND WARRANTS

       

      Section 3.1            Sale and Purchase of Notes; Closing.

       

      (a)     On the basis of the representations and warranties contained in, and subject to the terms and conditions of, this Purchase Agreement and the
        Indenture, the Issuer will issue to the Purchaser, and the Purchaser will be issued at an issue price of 100% of the aggregate principal amount thereof, on the Closing Date, the principal amount of November 2020 Notes set forth opposite the
        Purchaser’s name in Schedule 1.

       

      (b)    The Purchaser will receive the principal amount of November
        2020 Notes set forth in Schedule 1 on the Closing Date [or the Closing Payment, as the case may be], in consideration of the Repurchase described in Section 3.2 below (if applicable) and the Purchaser’s agreement to execute and deliver to
        the Issuer that certain written consent, substantially in the form attached hereto as Exhibit A (the “Consent”), which includes a consent to the execution and delivery of the Supplemental Indenture, and the consummation of the
        transactions contemplated hereby and thereby (collectively, the “Consideration”). The November 2020 Notes will be issued solely in exchange for the Consideration and the Purchasers shall be under no obligation to pay any cash consideration.
        Contemporaneously with entering into this Purchase Agreement, the Issuer is entering into separate purchase agreements (the “Other Agreements”) with other purchasers (the “Other Purchasers”), providing for the issuance on the Closing
        Date to each of the Other Purchasers of the November 2020 Notes in the principal amount specified opposite its name in Schedule 1 to such Other Agreement. The Issuer shall not be obligated to deliver, and the Purchaser shall not be required
        to purchase, any of the November 2020 Notes except upon (i) delivery of all the Notes to be purchased by the Other Purchasers under the Purchase Agreements on the Closing Date, (ii) the execution and delivery of the Consent by all holders of the
        2019 Notes, and (iii) the effectiveness of the Supplemental Indenture on the Closing Date, and in each case subject to the satisfaction or waiver of the respective terms and conditions hereunder and thereunder.

       

      (c)     On the Closing Date, simultaneously with the issuance of the November 2020 Notes, the Issuer will issue one or more Global Securities for the
        account of DTC, evidencing the aggregate principal amount of Notes to be acquired by all Purchasers pursuant to the Purchase Agreements as of the Closing Date.

       

      (d)     For U.S. federal income (and other applicable) tax purposes, each of the Issuer and the Purchaser acknowledge and agree that the transfer by the
        Issuer to the Purchaser of the November 2020 Notes pursuant to Section 3.1(b) is intended to be treated as a fee paid to the Purchaser for the Consent (the “Consent Fee”) and not as consideration for the purchase of the Notes.  For U.S.
        federal income (and other applicable) tax purposes the Issuer and the Purchaser agree to treat the Consent Fee, and shall file all tax returns, consistently with such treatment unless otherwise required by applicable law.

       

      
        2

        
          

      

      Section 3.2            Repurchase of 2019 Notes.

       

      (a)    [On the Closing Date, simultaneously with the issuance of the November 2020 Notes, the Issuer will redeem, by wire transfer, the aggregate principal
        amount of the 2019 Notes held by the Purchaser set forth opposite the Purchaser’s name on Schedule 1 hereto (the “Repurchased Notes”) for cash proceeds equal to 100.000% of the principal amount of the Repurchased Notes plus accrued and
        unpaid interest, if any, thereon to the Closing Date (the “Repurchase”).]2

       

      Section 3.3            Additional Securities and Warrants.

       

      (a)     Following the occurrence of the First Additional Securities Triggering Event (as defined in the Indenture) on or prior to December 31, 2021 and otherwise in accordance with Section 2.01(c)
        of the Indenture, the Purchaser agrees, at the election of the Issuer in its sole discretion and upon at least twenty (20) Business Days’ prior written notice by the Issuer to the Purchaser, to acquire the principal amount of First Additional Notes
        set forth opposite the Purchaser’s name in Schedule 1 hereto at an issue price of 100% of the aggregate principal amount thereof (such date, the “First Additional Notes Closing Date” and, together with the Closing Date, the “Applicable
          Closing Date”) for a cash payment on the First Additional Notes Closing Date in an amount equal to  100.000% of the principal amount of the First Additional Notes, delivered to the Issuer by wire transfer to an account  designated by the
        Issuer not less than three (3) Business Days prior to the First Additional Notes Closing Date.  The First Additional Notes shall be issued upon the terms and conditions set forth herein. If the Issuer elects to issue less than $10,000,000 of First
        Additional Notes, the Purchasers shall participate in such issuance on a pro rata basis (determined on the basis of the principal amount of First Additional Notes set forth opposite the Purchaser’s name in Schedule 1 hereto).

       

      (b)     The Purchaser shall have the right, upon prior written notice to the Issuer, to assign its rights and obligations to purchase First Additional Notes pursuant to the terms hereof; provided that the Purchaser shall not be released from its funding obligations so assigned to the extent such assignee fails to fund any portion of the obligations assigned to it on the First Additional Notes
        Closing Date.

       

      (c)     On the First Additional Notes Closing Date, the Issuer shall certify that, as of such date, each of the representations and warranties contained in the
          Purchase Agreement shall be true and correct in all material respects (except that any representation and warranty that is qualified as to “materiality” or “Material Adverse Effect” shall be true and correct in all respects) on and as of the
          First Additional Notes Closing Date, except to the extent such representations and warranties expressly related to any earlier date in which case such representations and warranties were true and correct as of such earlier date.  Purchaser
        shall have no obligation to purchase the First Additional Notes if a certificate certifying to the foregoing is not delivered to the Purchaser on the First Additional Notes Closing Date.

       

      
        
 

      2 Included in certain purchasers’ agreements.

       

      

      
        3

        
          

      

      (d)    Upon the occurrence of the Closing Date, the Issuer shall grant and issue to the Purchaser, for no additional consideration, warrants to purchase shares of common stock of the Issuer equal
        to the amount set forth opposite the Purchaser’s name on Schedule 1 hereto (collectively, the “Warrants”) at an exercise price per share of common stock equal to the volume weighted average price of a single share of the Issuer’s
        common stock in composite trading for the principal exchange on which such securities are listed for the thirty (30) trading days ending on, but excluding, the date of issuance, and otherwise substantially in accordance with the terms of those
        certain common stock purchase warrants issued by the Issuer to the initial purchasers of the Original Securities (as defined in the Indenture) on July 15, 2019.

       

      (e)     If, and solely to the extent that, the initial purchasers of the Original Securities (or their permitted transferees in accordance with the terms of the Indenture) purchase the First
        Additional Notes in accordance with Section 2.01(c) at the request of the Company following the occurrence of the First Additional Securities Triggering Event, if the First Additional Securities Triggering Event occurs on or prior to December 31,
        2021, the Issuer shall, on or before the tenth (10th) Business Day following the date of such issuance of the First Additional Notes, grant and issue to the Purchaser, for no additional consideration, warrants to purchase shares of
        common stock of the Issuer equal to 14.3 shares of common stock per $1,000 aggregate principal amount of First Additional Notes purchased by the initial purchasers of the Original Securities (or their permitted transferees in accordance with the
        terms of the Indenture), at an exercise price per share of common stock equal to the volume weighted average price of a single share of the Issuer’s common stock in composite trading for the principal exchange on which such securities are listed
        for the thirty (30) trading days ending on, but excluding, the date of issuance, and otherwise substantially in accordance with the terms of those certain common stock purchase warrants issued by the Issuer to the initial purchasers of the Original
        Securities on July 15, 2019.

       

      (f)     If, and solely to the extent that, the initial purchasers of the Original Securities elect to exercise the Right of First Offer (as defined in the Indenture) and purchase the Second
        Additional Notes following the occurrence of the Second Additional Securities Triggering Event (as defined in the Indenture), if the Second Additional Securities Triggering Event occurs on or prior to December 31, 2021, the Issuer shall, on or
        before the tenth (10th) Business Day following the date of such issuance of the Second Additional Notes, grant and issue to the Purchaser, for no additional consideration, warrants to purchase shares of common stock of the Issuer equal
        to (i) if the First Additional Notes have not been issued, 14.3 shares of common stock per $1,000 aggregate principal amount of Second Additional Notes purchased by the initial purchasers of the Original Securities until an aggregate of $10.0
        million of Second Additional Notes have been issued, and, (ii) thereafter,  28.5 shares of common stock per $1,000 aggregate principal amount of Second Additional Notes purchased by the initial purchasers of the Original Securities, in each case,
        at an exercise price per share of common stock equal to the volume weighted average price of a single share of the Issuer’s common stock in composite trading for the principal exchange on which such securities are listed for the thirty (30) trading
        days ending on, but excluding, the date of issuance, and otherwise substantially in accordance with the terms of those certain common stock purchase warrants issued by the Issuer to the initial purchasers of the Original Securities on July 15,
        2019. For the avoidance of doubt, if the First Additional Notes have not been issued, the warrants issued to the Purchasers in connection with the Second Additional Notes pursuant to each of clauses (f)(i) and (f)(ii) above shall be allocated to
        such Purchasers on a pro rata basis.

       

      
        4

        
          

      

      Section 3.4            [Closing Payment.

       

      (a)    On the Closing Date, the Issuer shall wire, in immediately available funds, to the Purchaser, at an account to be designated by the Purchaser, the Closing Payment in
        the amounts set forth opposite the Purchaser’s name in Schedule I.] 3

       

      ARTICLE IV

       

      REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF PURCHASER

       

      The Purchaser agrees and acknowledges that the Issuer and counsel to the Issuer may rely upon the accuracy of and performance of obligations under the representations, warranties and agreements of
        the Purchaser contained in this Article IV.

       

      Section 4.1            Purchase for
          Investment and Restrictions on Resales. The Purchaser:

       

      (a)     acknowledges that (i) neither the offer and sale of the Notes nor the issuance of the Warrants have been nor will be
        registered under the Securities Act or the Laws of any U.S. state or other jurisdiction relating to securities matters and (ii) neither the Notes nor the Warrants may be offered, sold, pledged or otherwise transferred except as set forth in the
        Transaction Documents and the legend regarding transfers on the Notes;

       

      (b)    agrees that, if it should resell or otherwise transfer the Notes or the Warrants, in whole or in part, it will do so
        only pursuant to an exemption from, or in a transaction not subject to, registration under the Securities Act, the Laws of any applicable state or other jurisdiction relating to securities matters and in accordance with the restrictions and
        requirements of the provisions of the Transaction Documents and the legend regarding transfers on the Notes and only to a Person whom it reasonably believes, at the time any buy order for such Notes or Warrants is
        originated, is (i) the Issuer or a Subsidiary of the Issuer, (ii) for so long as such Notes or Warrants are eligible for resale pursuant to Rule 144A, a QIB that purchases for its own account or for the account of a QIB, to which notice is given
        that the transfer is being made in reliance on Rule 144A, (iii) a Person outside the United States in an offshore transaction in compliance with Rule 903 or 904 of Regulation S (if available) or (iv) an Accredited Investor that is purchasing such
        Notes or Warrants for its own account or for the account of such an Accredited Investor for investment purposes and not with a view to, or for offer or sale in connection with, any distribution in violation of the Securities Act, in each case
        unless consented to by the Issuer in writing;

       

      (c)     acknowledges and agrees that, as a condition to the transfer of any Notes or the Warrants, each transferee of such
        Notes or Warrants shall be deemed to have given, and may be required expressly to give, the assurances set forth in Section 4.3 as to itself;

       

      (d)    acknowledges the restrictions and requirements contained in the Transaction Documents applicable to transfers of the Notes and the Warrants and the
        legend regarding transfers on the Notes and agrees that it will only offer or sell the Notes and the Warrants in accordance with such restrictions and requirements; and

       

      (e)    represents that it is purchasing the Notes for investment purposes and not with a view toward resale or distribution thereof in contravention of the
        requirements of the Securities Act; provided, however, that the Purchaser reserves the right to resell or otherwise transfer the Notes at any time in compliance with this Section 4.1 and in accordance with its investment objectives.

      

      

      

      3 Included in certain purchasers’ agreements.

       

      

      
        5

        
          

      

      Section 4.2         Purchaser
          Status. The Purchaser represents and warrants that, as of the date hereof, (a) if it is purchasing a Rule 144A Global Security or would purchase a Rule 144A Global Security except that it cannot or opts not to hold a beneficial interest in a
        Global Security, it is a QIB and is purchasing the Notes for its own account or for the account of a QIB, (b) if it is purchasing a Regulation S Global Security or would purchase a Regulation S Global Security except that it cannot or opts not to
        hold a beneficial interest in a Global Security, it is a Person outside the United States purchasing the Notes in an offshore transaction in compliance with Regulation S or (c) if neither clause (a) nor clause (b) is applicable, it is an Accredited
        Investor.

       

      Section 4.3            [Reserved].

       

      

      Section 4.4        
        Due Diligence. The Purchaser acknowledges that, prior to the date of this Purchase Agreement, (a) it has made, either alone or together with its advisors, such separate and independent investigation of the Issuer and its business, financial
        condition, prospects and management as the Purchaser deems to be, or such advisors have advised to be, necessary or advisable in connection with the purchase of the Notes pursuant to the transactions contemplated by this Purchase Agreement, (b) it
        and its advisors have received all information and data that it and such advisors believe to be necessary in order to reach an informed decision as to the advisability of the purchase of the Notes pursuant to the transactions contemplated by this
        Purchase Agreement, (c) it understands the nature of the potential risks and potential rewards of the purchase of the Notes, (d) it is a sophisticated investor with investment experience and has the ability to bear complete loss of its investment,
        whether as a result of an Event of Default on the Notes or any insolvency, liquidation or winding up of the Issuer or otherwise, and (e) it has such knowledge and experience in financial and business matters that it is capable of evaluating the
        merits and risks of purchasing the Notes and can bear the economic risks of investing in the Notes for an indefinite period of time, including the complete loss of its investment. The Purchaser acknowledges that it has obtained its own attorneys,
        business advisors and tax advisors as to legal, business and tax advice (or has decided not to obtain such advice) and has not relied in any respect on the Issuer for such advice. The Purchaser has had a reasonable time prior to the date of this
        Purchase Agreement to ask questions and receive answers concerning the Issuer and its business and the terms and conditions of the offering of the Notes and the transactions contemplated hereby and to obtain any additional information that the
        Issuer possesses or could acquire without unreasonable effort or expense, and has generally such knowledge and experience in business and financial matters and with respect to investments in securities as to enable the Purchaser to understand and
        evaluate the risks of such investment and form an investment decision with respect thereto. Except for (i) the representations, warranties and covenants made by the Issuer in the Transaction Documents and (ii) the legal opinions provided to the
        Purchaser in connection with the transactions contemplated by the Transaction Documents, the Purchaser is relying on its own investigation and analysis in entering into the transactions contemplated hereby.

       

      Section 4.5          Enforceability
          of this Purchase Agreement. This Purchase Agreement has been duly authorized, executed and delivered by the Purchaser and constitutes the valid, legally binding and enforceable obligation of the Purchaser, except as enforceability may be
        limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors’ rights generally and by general principles of equity.

       

      
        6

        
          

      

      Section 4.6           
        Tax Matters.

       

      

      (a)     Except as otherwise required by Law, the Purchaser agrees to treat, and shall treat, the Notes as indebtedness of the Issuer for U.S. federal
        income tax purposes.

       

      (b)    The Purchaser understands and acknowledges that, if Definitive Securities are issued, the Purchaser must provide the Issuer, the Trustee or any
        Paying Agent with the applicable U.S. federal income tax certifications (generally, on IRS Form W-9 (or successor applicable form) in the case of a Person that is a United States person (for purposes of this Section 4.6(b), within the meaning of
        Section 7701(a)(30) of the Code) or on an appropriate IRS Form W-8 (or successor applicable form) in the case of a Person that is not a United States person).

       

      (c)    The Purchaser represents and warrants that (i) it has not relied upon the Issuer for any tax advice or disclosure of tax consequences arising from
        the purchase, ownership or disposition of the Notes or the Warrants and (ii) it has relied upon its own tax counsel or advisors with respect to any tax consequences arising from the purchase, ownership or disposition of the Notes or the Warrants.

       

      Section 4.7         Reliance for
          Opinions. The Purchaser acknowledges and agrees that the Issuer and, for purposes of the opinions to be delivered to the Purchaser pursuant to Section 6.1, counsel for the Issuer may rely, without any independent verification thereof, upon
        the accuracy of the representations and warranties of the Purchaser, and compliance by the Purchaser with its agreements, contained in Sections 4.1 and 4.2, and the Purchaser hereby consents to such reliance.

       

      Section 4.8            2019 Notes. The Purchaser has good and marketable title to the
        Repurchased Notes, free and clear of all Liens or restrictions.

       

      ARTICLE V

       

      REPRESENTATIONS AND WARRANTIES OF THE ISSUER

       

      The Issuer represents and warrants to the Purchaser as of the date hereof as follows:

       

      Section 5.1            Securities Laws.

       

      

      (a)     No securities of the same class (within the meaning of Rule 144A(d)(3)(i) under the Securities Act) as the Notes or
        the Warrants have been issued and sold by the Issuer within the six-month period immediately prior to the date hereof.

       

      (b)    Assuming the accuracy of the representations and warranties of the Purchasers in each of the Purchase Agreements,
        neither the Issuer nor any affiliate (as defined in Rule 144 under the Securities Act) of the Issuer has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of any security (as
        defined in the Securities Act) that is or will be integrated with the sale of the Notes or the Warrants in a manner that would require the registration under the Securities Act of the Notes or the Warrants, (ii) engaged in any form of general
        solicitation or general advertising in connection with the offering of the Notes or the Warrants (as those terms are used in Regulation D under the Securities Act), or in any manner involving a public offering within the meaning of Section 4(a)(2)
        of the Securities Act, including publication or release of articles, notices or other communications published in any newspaper, magazine or similar medium or broadcast over television, radio or internet, or any seminar or meeting whose attendees
        have been invited by any general solicitation or general advertising, or (iii) engaged in any directed selling efforts within the meaning of Rule 902(c) of Regulation S.

       

      
        7

        
          

      

      (c)    Assuming the accuracy of the representations and warranties of the Purchasers in each of the Purchase Agreements, (i)
        the Indenture is not required to be qualified under the U.S. Trust Indenture Act of 1939, as amended, and (ii) no registration under the Securities Act of the Notes or the Warrants is required in connection with the
        sale thereof to the Purchasers as contemplated by the Transaction Documents.

       

      Section 5.2          Investment Company Act Matters. After giving effect to the offering
        and sale of the Notes and the issuance of the Warrants, the Issuer will not be required to register as an “investment company” or “controlled” by an “investment company” within the meaning of the U.S. Investment Company Act of 1940, as amended.

       

      Section 5.3            Apomorphine Purchase Agreement.

       

      

      (a)     The Apomorphine Purchase Agreement has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company and is enforceable against the
        Company.

       

      (b)    Pursuant to the Apomorphine Purchase Agreement, the Company shall receive (i) an up-front purchase price of $40,000,000 received substantially concurrently with the closing of such sale and
        (ii) additional contingent payments of up to $85,000,000 in the aggregate due upon the attainment of certain specified royalty and commercial targets.

       

      Section 5.4            Exchange Act Documents. The documents filed by the Issuer with the Commission pursuant to the
        Exchange Act since December 31, 2019 (excluding any documents or portions thereof furnished to, rather than filed with, the Commission) (such documents, the “Exchange Act Documents”), when they were filed with the Commission, conformed as to
        form in all material respects with the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the
        light of the circumstances under which they were made, not misleading.

       

      Section 5.5            Financial Statements. The financial
        statements included in the Exchange Act Documents, together with the related notes and schedules, present fairly in all material respects the consolidated financial position of the Issuer as of the respective dates indicated and the consolidated
        results of operations, cash flows and changes in shareholders’ equity of the Issuer for the respective periods specified and have been prepared in all material respects in compliance with the requirements of the Exchange Act and in conformity with
        GAAP applied on a consistent basis during the periods covered thereby, except as may be expressly stated in the related notes thereto and, in the case of unaudited financial statements, subject to normal and recurring year-end adjustments that, if
        presented, would not differ materially from that included in the audited financial statements. The other financial and accounting data of the Issuer contained in the Exchange Act Documents are accurately and fairly presented and prepared on a basis
        consistent with the financial statements or the books and records of the Issuer in all material respects.

       

      
        8

        
          

      

      Section 5.6            Organization; Power; Authorization; Enforceability. The Issuer has
        been duly organized, is legally existing and is in good standing under the Laws of the State of Delaware. The Issuer does not have any Subsidiaries except the following Immaterial Subsidiaries: Midasol Therapeutics, GP; and Midasol Therapeutics,
        LP. MSRX US, LLC has had its existence as a Delaware limited liability company canceled, and such entity did not at any point have any material assets, liabilities or operations. The Issuer is duly qualified as a foreign corporation (or other
        equivalent entity) in all jurisdictions in which the nature of its business or location of its properties require such qualifications, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect.
        The Issuer has the requisite corporate power and authority to own, lease or operate the properties and assets it purports to own, lease or operate, to carry on its business as presently conducted and to execute, deliver and perform its obligations
        under each Transaction Document except where the failure to have such power and authority to own, lease or operate such properties and assets and carry on such business would not reasonably be expected to have a Material Adverse Effect. Each
        Transaction Document entered into as of the date hereof has been duly authorized, executed and delivered by the Issuer and constitutes the valid, legally binding and, assuming due authorization, execution and delivery by all other parties thereto,
        enforceable obligation of the Issuer (subject, in each case, to general equitable principles, insolvency, liquidation, reorganization and other Laws of general application relating to creditors’ rights). Each Transaction Document to be entered into
        after the date hereof will be duly authorized, executed and delivered by the Issuer and will constitute the valid, legally binding and, assuming due authorization, execution and delivery by all other parties thereto, enforceable obligation of the
        Issuer (subject, in each case, to general equitable principles, insolvency, liquidation, reorganization and other Laws of general application relating to creditors’ rights).

       

      Section 5.7           
        Organizational Information. The Issuer’s principal place of business is Warren, New Jersey. The Issuer’s U.S. taxpayer identification number is 82-3827296.

       

      Section 5.8            Common Stock. The shares of Common Stock of the Issuer to be
        issued upon the exercise of the Warrants have been reserved by the Issuer and, upon exercise of the Warrants in accordance with their terms, will be validly issued, fully paid and non-assessable.

       

      Section 5.9            [Reserved].

       

      

      
        9

        
          

      

      Section 5.10          Governmental and Third Party Authorizations. No consent, approval,
        authorization, license, registration, qualification or order of, or filing or declaration with, any Governmental Authority, any self-regulatory organization or any other non-governmental regulatory authority (including the Nasdaq Stock Market LLC)
        or approval of the shareholders of the Issuer or any other Person is required in connection with (a) the execution or delivery by the Issuer of any Transaction Document or the performance of obligations by the Issuer under any Transaction Document
        (including the issuance and sale of the Notes and the issuance of the Warrants), (b) the transactions contemplated by the Transaction Documents, (c) the grant by the Issuer of the Liens granted or purported to be granted by it pursuant to the
        Security Documents or (d) the perfection of the Liens created under the Security Documents, other than (i) such consents, approvals, authorizations, licenses, registrations, qualifications, orders, filings, declarations and other actions as shall
        have been taken, given, made or obtained and are in full force and effect as of the Applicable Closing Date, in each case, as set forth in Schedule 5.10, (ii) any necessary filings under the securities or blue sky Laws of the various
        jurisdictions in which the Notes and the Warrants are being offered, (iii) the filing of financing statements under the UCC and recordings with the PTO and the filing of any other recordings (including in any applicable non-U.S. jurisdiction)
        required to perfect a security interest in the Notes Collateral and (iv) such consents, approvals, authorizations, licenses, registrations, qualifications, orders, filings, declarations and other actions, the failure of which to take, give, make or
        obtain would not reasonably be expected to have a Material Adverse Effect.

       

      Section 5.11      
           No Conflicts. The execution, delivery and performance of each Transaction Document by the Issuer, the issuance and sale of the Notes, the issuance of the Warrants and the consummation of the transactions contemplated by the Transaction
        Documents will not conflict with, result in any breach or violation of or constitute a default under (nor constitute any event that, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give
        the holder of any indebtedness (or a Person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (or result in the creation or imposition of a Lien on any property
        or assets of the Issuer pursuant to) (a) the certificate of incorporation or bylaws of the Issuer, (b) any indenture, mortgage, deed of trust, bank loan, credit agreement, other evidence of indebtedness, license, lease, contract or other agreement
        or instrument to which the Issuer is a party or by which it or its properties may be bound or affected, (c) any Law or (d) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority (including the
        rules and regulations of the Nasdaq Stock Market LLC), except, in the case of clause (b), (c) or (d), where such conflict, breach, violation, default, event, right or Lien would not reasonably be expected, individually or in the aggregate, to have
        a Material Adverse Effect.

       

      Section 5.12         No Violation or Default. The Issuer is
        not in breach or violation of or in default under (nor has any event occurred that, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a Person
        acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (a) its certificate of incorporation or bylaws, (b) any indenture, mortgage, deed of trust, bank loan, credit
        agreement, other evidence of indebtedness, license, lease, contract or other agreement or instrument to which it is a party or by which it or any of its properties may be bound or affected, (c) any Law or (d) any rule or regulation of any
        self-regulatory organization or other non-governmental regulatory authority (including the rules and regulations of the Nasdaq Stock Market LLC), except, in the case of clause (b), (c) or (d), where such breach, violation, default, event or right
        would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. On the Applicable Closing Date, no Event of Default on the Notes exists.

       

      
        10

        
          

      

      Section 5.13         No Material Adverse Change. Except as
        disclosed in the Exchange Act Documents, subsequent to the respective dates as of which information is given in the Exchange Act Documents, (a) there has not been any material change in the Capital Stock or long-term debt of the Issuer or any
        material adverse change, or any development that would be expected to result in a material adverse change, in or affecting the business, condition (financial or otherwise), results of operations, earnings, properties or prospects of the Issuer and
        its Subsidiaries taken as a whole, (b) the Issuer has not incurred any material liabilities or obligations, direct or contingent, nor has it entered into any material transactions not in the ordinary course of business, other than pursuant to the
        Transaction Documents and the transactions referred to herein and therein, (c) the Issuer has not and will not have paid or declared any dividends or other distributions of any kind on any class of its Capital Stock, (d) the Issuer has not
        sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any Governmental Authority
        and (e) the Issuer has not altered its method of accounting.

       

      Section 5.14        Compliance with ERISA. The Issuer has not
        maintained or contributed to a defined benefit plan as defined in Section 3(35) of ERISA. No plan maintained or contributed to by the Issuer that is subject to ERISA (an “ERISA Plan”) (or any trust created thereunder) has engaged in a
        “prohibited transaction” within the meaning of Section 406 of ERISA or Section 4975 of the Code that could subject the Issuer to any material tax penalty on prohibited transactions and that has not adequately been corrected. Each ERISA Plan is in
        compliance in all material respects with all reporting, disclosure and other requirements of the Code and ERISA as they relate to such ERISA Plan, except for any noncompliance that would not result in the imposition of a material tax or monetary
        penalty. With respect to each ERISA Plan that is intended to be “qualified” within the meaning of Section 401(a) of the Code, either (a) a determination letter has been issued by the IRS stating that such ERISA Plan and the attendant trust are
        qualified thereunder or (b) the remedial amendment period under Section 401(b) of the Code with respect to the establishment of such ERISA Plan has not ended and a determination letter application will be filed with respect to such ERISA Plan prior
        to the end of such remedial amendment period. The Issuer has never completely or partially withdrawn from a “multiemployer plan”, as defined in Section 3(37) of ERISA.

       

      Section 5.15          Tax Matters. The Issuer has filed all
        income and franchise tax returns and all other material tax returns required to be filed by it and has paid all taxes required to be paid by it and, if due and payable, any related or similar assessment, fine or penalty levied against it (except
        for any such taxes, assessments, fines or penalties currently being contested in good faith and for which adequate reserves in accordance with GAAP are being maintained or in any case in which the failure to file or pay, individually or
        collectively, would not reasonably be expected to have a Material Adverse Effect). The Issuer has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 5.5 in respect of all material federal,
        state and foreign income and franchise taxes for all periods as to which the tax liability of the Issuer has not been finally determined. The Issuer is not aware of any material claims against it by any taxing authority in relation to the filing of
        tax returns or the payment of required taxes, assessments, fines or penalties.

       

      Section 5.16       Legal Proceedings. Except as
        disclosed in the Exchange Act Documents, there are no actions, suits or proceedings pending or, to the Issuer’s knowledge, threatened against or affecting, the Issuer or any of its officers in their capacity as such before or by any Governmental
        Authority or the Financial Industry Regulatory Authority, Inc. or the Nasdaq Stock Market LLC, wherein an unfavorable ruling, decision or finding could reasonably be expected to result in a Material Adverse Effect. Except as set forth in the
        Exchange Act Documents, the Issuer has not received any written notice of proceedings relating to the revocation or modification of any authorization, approval, order, license, certificate, franchise or permit, where such revocation or modification
        would reasonably be expected to result in a Material Adverse Effect. There are no pending investigations known to the Issuer involving the Issuer by any Governmental Authority having jurisdiction over the Issuer or its business or operations that
        would reasonably be expected to result in a Material Adverse Effect.

       

      
        11

        
          

      

      Section 5.17        Solvency. No step has been taken or is
        currently intended by the Issuer or, to the knowledge of the Issuer, any other Person for the winding-up, liquidation, dissolution or administration or for the appointment of a receiver or administrator of the Issuer for all or any of its
        properties or assets. Immediately after the issuance and sale of the Notes and the consummation of the other transactions contemplated by the Transaction Documents on the Applicable Closing Date, the Issuer will not be rendered insolvent within the
        meaning of 11 U.S.C. 101(32) or any other applicable insolvency Laws or, taken as a whole, be unable to pay its debts as they mature.

       

      Section 5.18         Existing Indebtedness. The Exchange Act
        Documents disclose all of the following types of material third-party outstanding indebtedness of the Issuer as of the Applicable Closing Date: (a) indebtedness in respect of borrowed money; (b) any other obligation of the Issuer to be liable for,
        or to pay, as obligor, guarantor or otherwise, on the indebtedness for borrowed money of another Person (other than by endorsement of negotiable instruments for collection in the ordinary course of business); and (c) to the extent not otherwise
        included, indebtedness for borrowed money of another Person secured by a Lien on any asset owned by such Person (whether or not such indebtedness for borrowed money is assumed by such Person).

       

      Section 5.19        Material Contracts. There is no document
        or agreement of a character required to be described in the Exchange Act Documents or to be filed as an exhibit to the Exchange Act Documents that is not described or filed as required. All Material Contracts are in full force and effect and
        constitute the valid, legally binding and (subject to general equitable principles and insolvency, liquidation, reorganization and other Laws of general application relating to creditors’ rights) enforceable obligation of the Issuer and, to the
        knowledge of the Issuer, all other parties thereto, except in each case as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Issuer, there are no oral waivers or modifications (or pending requests therefor)
        in respect of any Material Contract except as would not reasonably be expected to have a Material Adverse Effect. The Issuer is not in breach or default under or with respect to any Material Contract binding on it except where such breaches or
        defaults would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Issuer, no other Person party to any Material Contract is in default thereunder except where such default would not reasonably be expected to have
        a Material Adverse Effect. To the knowledge of the Issuer, no party to any Material Contract has given any notice of termination or breach of any Material Contract.

       

      Section 5.20          Properties. The Issuer has good and
        marketable title to all properties and assets described in the Exchange Act Documents as being owned by it, free and clear of all Liens or restrictions other than Permitted Liens and the Liens created by the Security Documents, except as set forth
        in the Exchange Act Documents or those where the failure to have such title would not, individually or in the aggregate, have a Material Adverse Effect. To the knowledge of the Issuer, the Issuer has valid, subsisting and (subject to general
        equitable principles and insolvency, liquidation, reorganization and other Laws of general application relating to creditors’ rights) enforceable leases for the properties described in the Exchange Act Documents as leased by it, with such
        exceptions as are not material and do not materially interfere with the use made and proposed to be made of such properties by the Issuer.

       

      
        12

        
          

      

      Section 5.21          Intellectual Property.

       

      (a)    Except as disclosed in the Exchange Act Documents, the Issuer owns, has valid and enforceable licenses for or otherwise has adequate rights to use
        all technology (including patented, patentable and unpatented inventions and unpatentable proprietary or confidential information, systems or procedures), designs, processes, patents, trademarks, service marks, trade secrets, trade names, know how,
        copyrights and other works of authorship, computer programs, technical data and information and all similar intellectual property or proprietary rights (including all registrations and applications for registration of, and all goodwill associated
        with, any of the foregoing, as applicable) (collectively, “Intellectual Property”) that are material to its business as currently conducted or as proposed to be conducted, including the development, manufacture, operation and sale of any of
        the Issuer’s products or product candidates, as described in the Exchange Act Documents, except where the failure to own, license or otherwise have rights to such Intellectual Property would not, individually or in the aggregate, reasonably be
        expected to have a Material Adverse Effect. Except as disclosed in the Exchange Act Documents, the Intellectual Property of the Issuer has not been adjudged by a Governmental Authority of competent jurisdiction invalid or unenforceable in whole or
        in part, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as disclosed in the Exchange Act Documents: (i) to the knowledge of the Issuer, there are no third parties who have, or
        will be able to establish, rights to any Intellectual Property owned by or licensed to the Issuer, except for, and to the extent of, the rights of any third parties that are licensors or licensees of such Intellectual Property as set forth in Schedule
          5.21; (ii) to the Issuer’s knowledge, there is no infringement, misappropriation or other violation by third parties of any Intellectual Property owned by, or licensed to, the Issuer; (iii) there is no pending or, to the knowledge of the
        Issuer, threatened action, suit, proceeding or claim by others against the Issuer challenging the Issuer’s rights in or to any Intellectual Property owned by, or licensed to, the Issuer, and the Issuer is unaware of any facts that could form a
        reasonable basis for any such action, suit, proceeding or claim; (iv) there is no pending or, to the knowledge of the Issuer, threatened action, suit, proceeding or claim by others against the Issuer challenging the validity, enforceability or
        scope of any Intellectual Property owned by, or licensed to, the Issuer, and the Issuer is unaware of any facts that could form a reasonable basis for any such action, suit, proceeding or claim; (v) there is no pending or, to the knowledge of the
        Issuer, threatened action, suit, proceeding or claim by others against the Issuer that (nor has the Issuer received any written claim from a third party that) the Issuer infringed, misappropriated or otherwise violated, or is infringing,
        misappropriating or otherwise violating, any intellectual property rights of others, and the Issuer is unaware of any facts that could form a reasonable basis for any such action, suit, proceeding or claim; and (vi) the Issuer has complied with and
        there has been no breach or default by the Issuer under the terms of each agreement pursuant to which Intellectual Property has been licensed to the Issuer, and all such agreements are in full force and effect, except, in each case of clauses (i)
        through (vi), as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as set forth in the Exchange Act Documents, the Issuer is not obligated or under any liability whatsoever to make any
        material payment by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any Intellectual Property, with respect to the use thereof in connection with the conduct of its business or otherwise. No Immaterial
        Subsidiary owns or licenses any material Intellectual Property.

       

      
        13

        
          

      

      (b)    The Issuer owns, licenses or otherwise has the full exclusive right to use all material trademarks and trade names that are used in or reasonably
        necessary for the conduct of its business as described in the Exchange Act Documents, except where the failure to own, license or otherwise have rights to such trademarks and tradenames would not, individually or in the aggregate, reasonably be
        expected to have a Material Adverse Effect. The Issuer has not received any written notice of infringement of or conflict with asserted rights of others with respect to any such trademarks or trade names or challenging or questioning the validity
        or effectiveness of any such trademark or trade name. To the Issuer’s knowledge, the use of such trademarks and trade names in connection with the business and operations of the Issuer does not materially infringe on the rights of any Person.
        Except as set forth in the Exchange Act Documents, the Issuer is not obligated or under any liability whatsoever to make any material payment by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any trademark,
        service mark or trade name with respect to the use thereof in connection with the conduct of its business or otherwise.

       

      (c)    The Issuer has taken reasonable security measures to protect the secrecy, confidentiality and value of all its Intellectual Property in all material
        aspects, including complying with all material duty of disclosure requirements before the PTO and any other non-U.S. patent offices, as appropriate.

       

      (d)    Schedule 5.21 contains a complete list of (i) all registered trademarks, copyrights and Patents that are owned by the Issuer, in each case
        that are reasonably necessary for the operation of the business of the Issuer as presently conducted, and (ii) all Patent license agreements granting exclusive rights to the Issuer to such licensed Patents.

       

      (e)    The Issuer is the owner or holder of each new drug application or abbreviated new drug application set forth opposite its name in Schedule 5.21.
        Except as set forth in Schedule 5.21, the Issuer has not granted, assigned or licensed to any Person, directly or indirectly, any rights under any such new drug application or abbreviated new drug application. Schedule 5.21 sets
        forth the product that pertains to each such new drug application and abbreviated new drug application (and whether or not approval of any such drug application has been granted in any jurisdiction, and, if so, in which jurisdictions such approvals
        have been granted).

       

      
        14

        
          

      

      Section 5.22         Environmental Matters. Except in each case as would not individually or in the aggregate reasonably be expected to result in a Material Adverse Effect, (a) the Issuer is and has been in compliance with, and is
        not subject to any pending or, to the knowledge of the Issuer, threatened costs or liability under, any and all applicable Laws (including common law), and applicable and binding judicial or administrative decisions or orders, relating to
        pollution, the generation, use, handling, transportation, treatment, storage, discharge, disposal or release of Hazardous Substances, the protection or restoration of the environment, human health and safety, noise or the protection of natural
        resources, including wildlife, migratory birds, eagles or endangered or threatened species or habitats (collectively, “Environmental Laws”) and, to the knowledge of the Issuer, no facts or circumstances currently exist that would reasonably
        be expected to result in such non-compliance, cost or liability, (b) to the knowledge of the Issuer, the Issuer does not own, occupy, operate, lease or use any real property contaminated with Hazardous Substances in violation of Environmental Laws
        and that would reasonably be expected to result in the Issuer incurring any liability, (c) the Issuer is not conducting or funding any investigation, remediation, remedial action or monitoring of actual or suspected Hazardous Substances in the
        environment, (d) to the knowledge of the Issuer, the Issuer is not subject to any pending or threatened liability for any release or threatened release of Hazardous Substances, including at any off-site treatment, storage or disposal site, (e) the
        Issuer is not subject to any written claim, action, suit, order, demand or notice by any Governmental Authority or Person alleging liability or violation relating to Environmental Laws or Hazardous Substances, (f) the Issuer has received and is in
        compliance with all, and has received no written claim of liability under any, permits, licenses, authorizations, identification numbers or other approvals required under applicable Environmental Laws to conduct its business, as currently
        conducted, and (g) to the knowledge of the Issuer, there are no new requirements applicable to the conduct of the Issuer’s business, as currently conducted, proposed for adoption or implementation under any Environmental Law. Except as set forth in
        the Exchange Act Documents, there are no judicial or administrative proceedings that are pending, or known to be contemplated, against the Issuer pursuant to any Environmental Laws by a Governmental Authority, other than such proceedings for which
        it is reasonably believed no monetary sanctions of $100,000 or more will be imposed. Except as set forth in the Exchange Act Documents, the Issuer has not incurred, and does not currently anticipate incurring, any costs or expenditures (including
        capital expenditures) required under or pursuant to Environmental Laws that would reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Issuer.

       

      Section 5.23         Labor Matters. The Issuer is not involved
        in any labor dispute except where the dispute would not, individually or in the aggregate, have a Material Adverse Effect, nor, to the knowledge of the Issuer, is any such dispute threatened. The Issuer is currently in compliance with all
        applicable Laws relating to employment and labor, including those related to wages, hours, collective bargaining and the payment and withholding of Taxes.

       

      Section 5.24          Insurance. The Issuer carries, or is
        covered by, insurance in such amounts and covering such risks as the Issuer believes are adequate for the conduct of its business and the value of its properties and is customary for companies engaged in similar industries, and all such insurance
        is in full force and effect. The Issuer has no reason to believe that it will not be able to (a) renew its existing insurance coverage as and when such policies expire or (b) obtain comparable coverage from similar institutions as may be necessary
        or appropriate to conduct its business as currently conducted or proposed to be conducted and at a cost that would not, individually or in the aggregate, result in a Material Adverse Effect. The Issuer has not been denied any insurance coverage
        that it has sought or for which it has applied.

       

      

      
        15

        
          

      

      Section 5.25         No Unlawful Payments. None of the Issuer,
        any of its directors or officers or, to the Issuer’s knowledge, any agent, employee or representative of the Issuer or its Affiliates or other Person associated with or acting on behalf of the Issuer has (a) used any corporate funds for any
        unlawful contribution, gift, entertainment or other unlawful expense relating to political activity, (b) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment of corporate funds or
        benefit to any government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization, or any Person acting in an official capacity for or on behalf of any of the foregoing,
        or any political party or party official or candidate for political office, (c) taken any action, directly or indirectly, that would result in a violation of any provision of the FCPA, the U.K. Bribery Act 2010, or any applicable Law implementing
        the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offense under any other applicable anti-bribery or anti-corruption Laws, or (d) made, offered, agreed to, requested or
        taken an act in furtherance of any unlawful bribe or other unlawful benefit, including any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Issuer and, to the knowledge of the Issuer, its Affiliates
        have conducted their businesses in compliance with the FCPA and have instituted, maintained and enforced, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable anti-bribery
        and anti-corruption Laws.

       

      Section 5.26         Compliance with Anti-Money Laundering Laws.
        The operations of the Issuer are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
        those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering Laws
        of all jurisdictions in which the Issuer conducts business (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any Governmental Authority involving the Issuer with respect to the Anti-Money
        Laundering Laws is pending or, to the knowledge of the Issuer, threatened.

       

      Section 5.27         Sanctions. None of the Issuer or any director or officer of the Issuer
        or, to the knowledge of the Issuer, any agent, employee or representative of the Issuer or any Affiliate or other Person associated with or acting on behalf of the Issuer is currently the subject or target of any sanctions administered or enforced
        by the U.S. government (including the Office of Foreign Assets Control of the U.S. Treasury Department or the U.S. Department of State and including the designation as a “specially designated national” or “blocked person”), the United Nations
        Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Issuer located, organized or resident in a country or territory that is the subject or the target of
        Sanctions, including Cuba, Iran, North Korea, the Crimean region and Syria (each, a “Sanctioned Country”). The Issuer will not directly or indirectly use the proceeds of the offering of the Notes, or lend, contribute or otherwise make
        available such proceeds to any Subsidiary, joint venture partner or other Person, (a) to fund or facilitate any activities of or business with any Person that, at the time of such funding or facilitation, is the subject or the target of Sanctions,
        (b) to fund or facilitate any activities of or business in any Sanctioned Country or (c) in any other manner that will result in a violation by any Person (including any Person participating in the transaction contemplated hereby, whether as
        underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Issuer has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person that at the time of
        the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

       

      
        16

        
          

      

      Section 5.28         Disclosure Controls. The Issuer has
        established and maintains disclosure controls and procedures (as such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act) that (a) are designed to ensure that material information relating to the Issuer is made known to the Issuer’s
        principal executive officer and principal financial officer by others within the Issuer, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared, (b) provide for the periodic evaluation of
        the effectiveness of such disclosure controls and procedures as of the end of the period covered by the Issuer’s most recent annual or quarterly report filed with the Commission and (c) are effective in all material respects to perform the
        functions for which they were established.

       

      Section 5.29          Accounting Controls.

       

      

      (a)    The Issuer maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in
        accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is
        permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any
        differences.

       

      (b)    Since the end of the Issuer’s most recent audited fiscal year, there has been (i) no material weakness (as defined in Rule 1-02 of Regulation S-X of
        the Commission) in the Issuer’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Issuer’s internal control over financial reporting that has materially affected, or is reasonably likely to materially
        affect, the Issuer’s internal control over financial reporting. The Issuer is not aware of (x) any significant deficiency in the design or operation of its internal control over financial reporting that is reasonably likely to adversely affect the
        Issuer’s ability to record, process, summarize and report financial data or any material weaknesses in its internal controls, except as disclosed in the Exchange Act Documents, since the end of the Issuer’s most recent audited fiscal year or (y)
        any fraud, whether or not material, that involves management or other employees who have a significant role in the Issuer’s internal controls.

       

      Section 5.30          Licenses and Permits. Except as would
        not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (a) the Issuer holds, and is operating in compliance with, such permits, licenses, franchises, registrations, exemptions, approvals, authorizations and
        clearances of any Governmental Authorities (including the FDA) required for the conduct of its business as currently conducted (collectively, the “Permits”), and all such Permits are in full force and effect, and (b) the Issuer has fulfilled
        and performed all of its obligations with respect to the Permits, and, to the Issuer’s knowledge, no event has occurred that allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other impairment
        of the rights of the holder of any Permit, other than, in each case, the Permits set forth in Schedule 5.30. All applications, notifications, submissions, information, claims, reports and statistics, and other data and conclusions derived
        therefrom, utilized as the basis for any and all requests for a Permit from the FDA or other Governmental Authority relating to the Issuer, its business and its products, when submitted to the FDA or other Governmental Authority by or on behalf of
        the Issuer, were true, complete and correct in all material respects. Any necessary or required updates, changes, corrections or modifications to such applications, notifications, submissions, information, claims, reports and statistics and other
        data have been submitted to the FDA or other Governmental Authority, other than, in each case, the Permits set forth in Schedule 5.30. The Issuer has not received any written notification, correspondence or other written communication,
        including notification of any pending or, to the Issuer’s knowledge, threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any Governmental Authority, including the FDA or the DEA, of potential
        or actual non-compliance by, or liability of, the Issuer under any Permits except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Issuer’s knowledge, no facts or circumstances
        currently exist that would reasonably be expected to give rise to any liability of the Issuer under any Permits except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

       

      
        17

        
          

      

      Section 5.31          Clinical Trials. The pre-clinical studies and clinical trials
        conducted by or, to the knowledge of the Issuer, on behalf of or sponsored by the Issuer, or in which the Issuer has participated, that are described in, or the results of which are referred to in, the Exchange Act Documents were and, if still
        pending, are being conducted in accordance with protocols filed with the appropriate regulatory authorities for each such study or trial, as the case may be, and with standard medical and scientific research standards and procedures, all applicable
        Laws (including those of the FDA and comparable regulatory agencies outside of the United States) to which they are subject and Good Clinical Practices and Good Laboratory Practices, except to the extent where failure to conduct such pre-clinical
        studies and clinical trials in such manner would not have a Material Adverse Effect. Each description of the results of such studies and trials contained in the Exchange Act Documents is accurate and complete in all material respects and fairly
        presents the data derived from such studies and trials, and the Issuer has no knowledge of any other studies or trials the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Exchange
        Act Documents. The Issuer has not received any written notices, correspondence or other written communications from the FDA or any committee thereof or from any other U.S. or non-U.S. government or drug or medical device regulatory agency
        (collectively, the “Regulatory Agencies”) requiring or, to the Issuer’s knowledge, threatening the termination, suspension or modification of any clinical trials that are described or referred to in the Exchange Act Documents. The Issuer has
        operated at all times and currently is in compliance with all applicable Laws of the Regulatory Agencies except where such failure to operate or non-compliance would not reasonably be expected, individually or in the aggregate, to result in a
        Material Adverse Effect.

       

      Section 5.32          Regulatory Filings. The Issuer has not failed to file with the
        Regulatory Agencies any required material filing, declaration, listing, registration, report or submission with respect to any products or product candidates that are described or referred to in the Exchange Act Documents or any other material
        filing required by any other applicable Regulatory Agency or other Governmental Authority. All such filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable Laws when filed. All such
        filings, declarations, listings, registrations, reports or submissions were timely, complete, accurate and not misleading on the date filed in all material respects (or were corrected or supplemented by subsequent submission). No material
        deficiencies regarding compliance with applicable Law have been asserted in writing by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions.

       

      
        18

        
          

      

      Section 5.33        Compliance with Certain Regulatory Matters. The Issuer, its directors
        and officers and, to the Issuer’s knowledge, its employees and agents have operated and currently are in compliance in all material respects with applicable Laws administered or enforced by the FDA, the DEA or any other Governmental Authority,
        including the Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. §3729 et seq.), the False Statements Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary
        Penalties Law (42 U.S.C. §1320a-7a), all criminal Laws relating to health care fraud and abuse, including 18 U.S.C. §§ 286 and 287, the exclusions law (42 U.S.C. § 1320a-7), the Laws of Medicare (Title XVIII of the Social Security Act), Medicaid
        (Title XIX of the Social Security Act) and all other government funded or sponsored healthcare programs, and the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information
        Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. §17921 et seq.). The Issuer is not a party to, and does not have any ongoing reporting obligations pursuant to, any corporate integrity agreement, deferred prosecution agreement,
        monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any Governmental Authority. Neither the Issuer nor, to the knowledge of the Issuer, any of its directors, officers, employees or agents has
        been debarred, excluded or suspended from participation in or receiving payment from any U.S. federal, state or local government health care program or is subject to an audit, investigation, proceeding or other similar action by any Governmental
        Authority that could reasonably be expected to result in debarment, suspension or exclusion.

       

      Section 5.34          Absence of Certain Regulatory Actions. Except as described in the
        Exchange Act Documents or as would not, individually or in the aggregate, have a Material Adverse Effect, the Issuer has not (a) had any product or manufacturing site (whether Issuer-owned or that of a contract manufacturer for Issuer products or
        product candidates) subject to a Governmental Authority (including the FDA) shutdown or import or export prohibition or (b) received any FDA Form 483 or other Governmental Authority notice of inspectional observations, “warning letters”, “untitled
        letters”, requests to make changes to the Issuer products, processes or operations, or similar written correspondence or notice from the FDA or other Governmental Authority alleging or asserting material noncompliance with any applicable Laws. To
        the Issuer’s knowledge, neither the FDA nor any other Governmental Authority has threatened such action. The Issuer has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other
        action from any Regulatory Agency or other Governmental Authority alleging that any product operation or activity is in violation of any health care Laws, and, to the Issuer’s knowledge, no such claim, action, suit, proceeding, hearing,
        enforcement, investigation, arbitration or other action is threatened, except where such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action would not reasonably be expected, individually or in the
        aggregate, to result in a Material Adverse Effect.

       

      Section 5.35         Collateral Agreement. The representations and warranties of the Issuer
        in Article III of that certain collateral agreement, dated July 15, 2019, among the Issuer, the other subsidiary parties from time to time party thereto, the Trustee and the Collateral Agent are true and correct in all material respects (except to
        the extent qualified by materiality, in which case such representation or warranty shall be true and correct in all respects).

       

      
        19

        
          

      

      ARTICLE VI

       

      CONDITIONS TO CLOSING

       

      The obligations of the Purchaser hereunder on the Applicable Closing Date are subject to the accuracy in all material respects (except for such representations qualified by materiality or Material
        Adverse Effect, which shall be accurate in all respects) of the representations and warranties of the Issuer contained herein as of the Applicable Closing Date, to the accuracy of the statements of the Issuer and its officers made in any
        certificates delivered pursuant hereto on the Applicable Closing Date, to the performance by the Issuer of its obligations hereunder as of the Applicable Closing Date and to the satisfaction or waiver by the Purchaser of each of the following
        additional terms and conditions applicable on the Applicable Closing Date:

       

      Section 6.1          Issuer’s Counsel
          Opinion. Dechert LLP, counsel to the Issuer, shall have furnished to the Purchasers their opinion, addressed to the Purchasers and dated the Applicable Closing Date, in form and substance reasonably satisfactory to the Purchasers.

       

      Section 6.2           Supplemental Indenture.  The Issuer shall have furnished to the Purchasers an executed copy of the Supplemental Indenture by and among the Issuer, the other subsidiary parties from time to time party
        thereto, the Trustee and the Collateral Agent.

       

      Section 6.3         Certification as to Purchase Agreement. The Issuer shall have furnished to the Purchasers a
        certificate, dated the Applicable Closing Date, of a Responsible Officer, stating that, as of the Applicable Closing Date, the representations and warranties of the Issuer in this Purchase Agreement are true and correct in all material respects
        (except for such representations qualified by materiality or Material Adverse Effect, which are true and correct in all respects) and the Issuer has complied in all material respects with all of the agreements and satisfied all of the conditions on
        its part to be performed or satisfied hereunder on or before the Applicable Closing Date.

       

      Section 6.4            Authorizations.
        The Issuer shall have furnished to the Purchasers (a) a copy of the resolutions, consents or other documents, certified by a Responsible Officer of the Issuer, as of the Applicable Closing Date, duly authorizing the execution and delivery of, and
        performance of obligations under, the Transaction Documents and any other documents to be executed on or prior to the Applicable Closing Date by or on behalf of the Issuer in connection with the transactions contemplated hereby and thereby, the
        issuance and sale of the Notes and the issuance of the Warrants, and a certification that such resolutions, consents or other documents have not been modified, rescinded or amended and are in full force and effect, (b) certified copies of its
        organizational documents, (c) a certification by a Responsible Officer, as of the Applicable Closing Date, as to the incumbency and specimen signatures of each officer executing any Transaction Document or any other document delivered in connection
        herewith or therewith on behalf of the Issuer (together with a certification of another Responsible Officer as to incumbency and specimen signature of the first-mentioned Responsible Officer) and (d) a certificate of good standing of the Issuer as
        of a recent date from the Secretary of State of the State of Delaware.

       

      Section 6.5            [Reserved].

       

      Section 6.6            [Reserved].

       

      

      
        20

        
          

      

      Section 6.7          Further Information. On or prior to the Applicable Closing Date, the
        Issuer shall have furnished to the Purchaser such further information, certificates and documents as the Purchaser may reasonably request in connection with this Purchase Agreement and the other Transaction Documents and the transactions
        contemplated hereby and thereby.

       

      Section 6.8            Consummation
          of Transactions. All of the transactions contemplated by the Transaction Documents to be completed on or before the Applicable Closing Date shall have been consummated or shall be consummated concurrently with the transactions contemplated
        hereby, and the Purchaser shall have received executed copies of the Transaction Documents (which shall be in full force and effect).

       

      Section 6.9            No Actions.
        No action shall have been taken and no Law shall have been enacted, adopted or issued by any Governmental Authority that would, as of the Closing Date, prevent the issuance or sale of the Notes, and no injunction, restraining order or order of any
        other nature by any Governmental Authority of competent jurisdiction shall have been issued as of the Closing Date that would prevent the issuance or sale of the Notes.

       

      Section 6.10        Consents. The Purchasers shall have received copies of all consents,
        approvals, authorizations, orders, registrations and qualifications set forth in Schedule 5.10, if any.

       

      

      ARTICLE VII

       

      ADDITIONAL COVENANTS

       

      Section 7.1            DTC. The
        Issuer will use reasonable best efforts to comply with the agreements set forth in the representation letter of the Issuer to DTC relating to the approval of the Notes by DTC for “book-entry” transfer.

       

      Section 7.2       
            Expenses. The Issuer agrees to pay or cause to be paid all reasonable, documented fees and expenses of Proskauer Rose LLP, acting as special counsel to the Purchasers (the amount of any such payment of the reasonable, documented fees
        and expenses of Proskauer Rose LLP (excluding such fees and expenses related to intellectual property work and opinions) not to exceed in the aggregate $100,000, it being understood that the Issuer will not reimburse any other expenses of any
        Purchasers (including expenses of any other counsel).

       

      Section 7.3            Confidentiality; Public Announcement.

       

      

      (a)    Except as otherwise required by Law or judicial or administrative proceedings (by oral questions, interrogatories, requests for information or
        documents, subpoena, civil investigation demand or similar process) or the rules and regulations of any securities exchange or trading system or any Governmental Authority or pursuant to requests from regulatory agencies having oversight over the
        Issuer and except as otherwise set forth in this Section 7.3, the Issuer will, and will cause each of its Affiliates, directors, officers, employees, agents, representatives and similarly situated Persons who receive such information to, treat and
        hold as confidential and not disclose to any Person any and all Confidential Information furnished to it by the Purchaser, as well as the information in Schedule 1, and to use any such Confidential Information and other information only in
        connection with this Purchase Agreement and any other Transaction Document and the transactions contemplated hereby and thereby. Notwithstanding the foregoing, the Issuer may disclose such information solely on a need-to-know basis and solely to
        its directors, employees, officers, agents, brokers, advisors, lawyers, bankers, trustees, representatives, investors, co-investors, insurers, insurance brokers, underwriters and financing parties; provided, however, that such
        Persons shall be informed of the confidential nature of such information and shall be obligated to keep such Confidential Information and other information confidential pursuant to obligations of confidentiality no less onerous than those set forth
        herein.

       

      
        21

        
          

      

      (b)    The Purchaser acknowledges that it will not, after the execution of this Purchase Agreement, make a public announcement or filing with respect to
        the transactions contemplated by the Transaction Documents or reference or describe such transactions in a public announcement or filing, without the Issuer’s prior written consent (such consent not to be unreasonably withheld, delayed or
        conditioned). Except as required by applicable Law or judicial or administrative proceedings (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigation demand or similar process) or the rules and
        regulations of any securities exchange or trading system or any Governmental Authority or pursuant to requests from regulatory agencies having oversight over the Issuer, in no event shall the Purchaser’s name (in any variation) be used in any
        public announcement or filing, or in any type of mail or electronic distribution intended for an audience that is not solely limited to the Affiliates of the Issuer, without the Purchaser’s written consent.

       

      (c)    Except as required by applicable Law or judicial or administrative proceedings (by oral questions, interrogatories, requests for information or
        documents, subpoena, civil investigation demand or similar process) or the rules and regulations of any securities exchange or trading system or any Governmental Authority or pursuant to requests from regulatory agencies having oversight over the
        Issuer, neither the Issuer nor any of its Affiliates shall disclose to any Person, or use or include in any public announcement or any public filing, the identity of any shareholders, members, directors or Affiliates of the Purchaser, without the
        prior written consent of such shareholder, member, director or Affiliate.

       

      ARTICLE VIII

       

      SURVIVAL OF CERTAIN PROVISIONS

       

      Section 8.1           Survival of
          Certain Provisions. The representations, warranties, covenants and agreements contained in this Purchase Agreement shall survive (a) the execution and delivery of this Purchase Agreement, the Notes and the Warrant and (b) the sale or transfer
        by any Purchaser of any Note or any Warrant or portion thereof or interest therein. All such provisions are binding upon and may be relied upon by any subsequent holder or beneficial owner of a Note or a Warrant, regardless of any investigation
        made at any time by or on behalf of any Purchaser or any other holder or beneficial owner of a Note or a Warrant. All statements contained in any certificate or other instrument delivered by or on behalf of either party hereto pursuant to this
        Purchase Agreement shall be deemed to have been relied upon by the other party hereto and shall survive the consummation of the transactions contemplated hereby regardless of any investigation made by or on behalf of either such party. The
        Transaction Documents embody the entire agreement and understanding between the parties hereto and supersede all prior agreements and understandings relating to the subject matter hereof. Notwithstanding anything to the contrary elsewhere in this
        Purchase Agreement, neither party hereto shall, in any event, be liable to any other Person for any consequential, incidental, indirect, special or punitive damages of such other Person, including loss of revenue, income or profits, diminution of
        value or loss of business reputation or opportunity relating to the breach or alleged breach hereof (provided, that such limitation with respect to lost profits or otherwise shall not limit the Issuer’s right to recover contract damages in
        connection with the Purchaser’s failure to close in violation of this Purchase Agreement).

       

      
        22

        
          

      

      ARTICLE IX

       

      NOTICES

       

      Section 9.1           Notices

       

      . All statements, requests, notices and agreements hereunder shall be in writing and delivered by hand, mail, overnight courier or telefax as follows:

       

      	

            	(a)	
              if to the Purchaser, in accordance with Schedule 1; and

            

       

      	

            	(b)	
              if to the Issuer, in accordance with Section 12.01 of the Indenture.

            

       

      ARTICLE X

       

      SUCCESSORS AND ASSIGNS

       

      Section 10.1          Successors and Assigns. This Purchase Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors, permitted assignees and permitted transferees.
        So long as any of the Notes or the Warrant are outstanding, the Issuer may not assign any of its rights or obligations hereunder or any interest herein without the prior written consent of the Purchaser except as permitted in accordance with the
        Indenture and the Warrant, as applicable.

       

      ARTICLE XI

       

      SEVERABILITY

       

      Section 11.1       Severability.
        Any provision of this Purchase Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
        hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by Law) not invalidate or render unenforceable such provision in any other jurisdiction.

       

      ARTICLE XII

       

      WAIVER OF JURY TRIAL

       

      Section 12.1          WAIVER OF JURY
          TRIAL. THE PURCHASER AND THE ISSUER HEREBY WAIVE TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO THIS PURCHASE AGREEMENT.

       

      

      ARTICLE XIII

       

      GOVERNING LAW; CONSENT TO JURISDICTION

       

      Section 13.1          Governing Law;
          Consent to Jurisdiction. THIS PURCHASE AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO
        CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS. The parties hereto hereby submit
        to the non-exclusive jurisdiction of the U.S. federal and state courts of competent jurisdiction in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Purchase Agreement or the transactions
        contemplated hereby.

       

      
        23

        
          

      

      ARTICLE XIV

       

      

      COUNTERPARTS

       

      Section 14.1          Counterparts.
        This Purchase Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Purchase Agreement. Any counterpart may be executed by
        facsimile or other electronic transmission, and such facsimile or other electronic transmission shall be deemed an original.

       

      ARTICLE XV

       

      TABLE OF CONTENTS AND HEADINGS

       

      Section 15.1          Table
          of Contents and Headings. The Table of Contents and headings of the Articles and Sections of this Purchase Agreement have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or
        restrict any of the terms or provisions hereof.

       

      ARTICLE XVI

       

      TAX DISCLOSURE

       

      Section 16.1         Tax Disclosure.
        Notwithstanding anything expressed or implied to the contrary herein, the Purchaser, on the one hand, and the Issuer, on the other hand, and its respective employees, representatives and agents may disclose to any and all Persons, without
        limitation of any kind, the tax treatment and the tax structure of the transactions contemplated by this Purchase Agreement and the agreements and instruments referred to herein and all materials of any kind (including opinions or other tax
        analyses) that are provided to such Person relating to such tax treatment and tax structure; provided, however, that neither such Person nor any employee, representative or other agent thereof shall disclose any other information
        that is not relevant to understanding the tax treatment and tax structure of such transactions (including the identity of any party and any information that could lead another to determine the identity of any party) or any other information to the
        extent that such disclosure could reasonably result in a violation of any Law relating to U.S. federal or state securities matters. For these purposes, the tax treatment of the transactions contemplated by this Purchase Agreement and the agreements
        and instruments referred to herein means the purported or claimed U.S. federal or state tax treatment of such transactions. Moreover, the tax structure of the transactions contemplated by this Purchase Agreement and the agreements and instruments
        referred to herein includes any fact that may be relevant to understanding the purported or claimed U.S. federal or state tax treatment of such transactions.

       

      {SIGNATURE PAGE FOLLOWS}

       

      
        24

        
          

      

      If the foregoing is in accordance with your understanding of this Purchase Agreement, kindly sign and return to us one of the counterparts hereof, whereupon it will become a binding agreement
        between us and you in accordance with its terms.

       

      	 	
              Very truly yours,

            
	 	
              AQUESTIVE THERAPEUTICS, INC.

            
	 	 
	 	
              By:

            
	 	 	
              Name:

            
	 	 	
              Title:

            

      

      

      {Signature Page to the Purchase Agreement}

      

      

      
        25

        
          

      

      [PURCHASER SIGNATURE PAGE]

       

      {Signature Page to the Purchase Agreement}

      

      

      
        26

        
          

      

      ANNEX A

       

      RULES OF CONSTRUCTION AND DEFINED TERMS

       

      Unless the context otherwise requires, in this Annex A and each Transaction Document (or other document) to which this Annex A is attached:

       

      	(a)	
              A term has the meaning assigned to it and an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP, unless any Transaction Document (or other document) otherwise provides.

            

       

      	(b)	
              Where any payment is to be made, any funds are to be applied or any calculation is to be made under any Transaction Document (or other document) on a day that is not a Business Day, unless any Transaction
                Document (or other document) otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly, including interest
                unless otherwise specified.

            

       

      	(c)	
              Words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders.

            

       

      	(d)	
              The definitions of terms shall apply equally to the singular and plural forms of the terms defined.

            

       

      	(e)	
              The terms “include”, “including” and similar terms shall be construed as if followed by the phrase “without limitation”.

            

       

      	(f)	
              Unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms
                thereof (subject to any restrictions on such amendments, restatements, reformations, supplements or modifications set forth in this Annex A or any Transaction Document (or other document)) and include any Annexes, Exhibits and
                Schedules attached thereto.

            

       

      	(g)	
              References to any Law shall include such Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor.

            

       

      	(h)	
              References to any Person shall be construed to include such Person’s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation set forth in this Annex A or any Transaction Document (or
                other document)), and any reference to a Person in a particular capacity excludes such Person in other capacities.

            

       

      	(i)	
              The word “will” shall be construed to have the same meaning and effect as the word “shall”.

            

       

      
        27

        
          

      

      	(j)	
              The words “hereof”, “herein”, “hereunder” and similar terms when used in this Annex A or any Transaction Document (or other document) shall refer to this Annex A or
                such Transaction Document (or other document) as a whole and not to any particular provision hereof or thereof, and Article, Section, Annex, Schedule and Exhibit references herein and therein are references to Articles and Sections of, and
                Annexes, Schedules and Exhibits to, the relevant Transaction Document (or other document) unless otherwise specified.

            

       

      	(k)	
              In the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and each of the words “to” and “until” means “to but excluding”.

            

       

      	(l)	
              References to any action, remedy or method of judicial proceeding for the enforcement of the rights of creditors or of security shall be deemed to include, in respect of any jurisdiction other than the State
                of New York, references to such action, remedy or method of judicial proceeding for the enforcement of the rights of creditors or of security available or appropriate in such jurisdiction as shall most nearly approximate such action, remedy
                or method of judicial proceeding described or referred to in the relevant Transaction Document (or other document).

            

       

      
        28

        
          

      

      “$” means lawful money of the United States.

       

      “2019 Notes” means the 12.5% Senior Secured Notes due 2025 of the Issuer in the initial outstanding principal balance of $70,000,000 that were issued on July 15, 2019 pursuant to Section
        2.01(b) of the Indenture and Section 3.1 of the related purchase agreements.

       

      “Accredited Investor” means an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3) or (a)(7) under the Securities Act that is not (i) a QIB or (ii) a Person other than a U.S.
        person (as defined in Regulation S) that acquires Notes or Warrants in reliance on Regulation S.

       

      “Affiliate” means, with respect to any specified Person, another Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control
        with the specified Person. For purposes of this definition, “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
        the Capital Stock of such Person that is at the time entitled to vote in the election of the board of directors (or equivalent) of such Person, by contract or otherwise, and “controlled” has a meaning correlative thereto.

       

      “Anti-Money Laundering Laws” has the meaning set forth in Section 5.26 of the Purchase Agreements.

       

      “Apomorphine Purchase Agreement” means that certain Purchase and Sale Agreement, dated as of November 3, 2020, between the Issuer and MAM Pangolin Royalty, LLC (the “Royalty Purchaser”)
        regarding, among other things, the assignment to the Royalty Purchaser of the Issuer’s rights to receive future royalty and milestone payments under the Sunovion License Agreement.

       

       “Business Day” means any day other than a Saturday, a Sunday or any other day on which banking institutions are authorized or required by Law to close in New York City or the city in which
        the Trustee’s corporate trust office is located.

       

      “Capital Stock” means (a) in the case of a corporation, corporate stock or shares, (b) in the case of an association or business entity, any and all shares, interests, participations, rights
        or other equivalents (however designated) of corporate stock, (c) in the case of a partnership or limited liability company, partnership or membership interests (whether general or limited) and membership rights, and (d) any other interest or
        participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person, in each case to the extent treated as equity in accordance with GAAP, but excluding from all of the
        foregoing any debt securities convertible into or exchangeable for Capital Stock whether or not such debt securities include any right of participation with Capital Stock.

       

      “Closing Date” means the tenth business day following the date the Initial Permitted Apomorphine Monetization (as defined in the Indenture) is funded.

       

      [“Closing Payment” means, in respect of each of [●], the amount of USD cash specified beside such Purchaser’s name in the column labeled “Closing
        Payment Amount” on Schedule 1 attached hereto.]

       

      “Code” means the U.S. Internal Revenue Code of 1986, as amended.

       

      
        29

        
          

      

      “Collateral Agent” means U.S. Bank National Association in its capacity as “Collateral Agent” under the Indenture and under the Security Documents and any successor thereto in such capacity.

       

      “Commission” means the U.S. Securities and Exchange Commission or any successor thereto.

       

      “Common Stock” means (i) the common stock, par value $0.001 per share, of the Issuer and (ii) any other Capital Stock into which such common stock is reclassified or reconstituted.

       

      “Confidential Information” means, as it relates to the Purchaser (or its Affiliates), all information (whether written or oral, or in electronic or other form) furnished before or after the
        date of this Purchase Agreement concerning the Purchaser or its Affiliates (including any of its equityholders), including any and all information regarding any aspect of the Purchaser’s business, including its owners, funds, strategy, market
        views, structure, investors or potential investors. Such Confidential Information includes any IRS Form W-9 or W-8BEN (or any similar type of form) provided by the Purchaser (or its Affiliates) to the Issuer or its Affiliates. Notwithstanding the
        foregoing definition, “Confidential Information” shall not include information that is (v) independently developed or discovered by the Issuer without use of or access to any information described in the second preceding sentence, as
        demonstrated by documentary evidence, (w) already in the public domain at the time the information is disclosed or has become part of the public domain after such disclosure through no breach of this Purchase Agreement, (x) lawfully obtainable from
        other sources, (y) required to be disclosed in any document to be filed with any Governmental Authority or otherwise required to be disclosed under applicable Law or judicial or administrative proceedings (by oral questions, interrogatories,
        requests for information or documents, subpoena, civil investigation demand or similar process) or pursuant to requests from regulatory agencies having oversight over the Issuer or (z) required to be disclosed by court or administrative order or
        under securities Laws applicable to any party to this Purchase Agreement or pursuant to the rules and regulations of any stock exchange or stock market on which securities of the Issuer or its Affiliates or the Purchaser or its Affiliates may be
        listed for trading.

       

      “DEA” means the U.S. Drug Enforcement Administration or any successor thereto.

       

      “Definitive Security” has the meaning set forth in Appendix A to the Indenture as of the date of the Purchase Agreements.

       

      “DTC” means The Depository Trust Company (including its nominees).

       

      “Environmental Laws” has the meaning set forth in Section 5.22 of the Purchase Agreements.

       

      “ERISA” means the U.S. Employee Retirement Income Security Act of 1974, as amended.

       

      “ERISA Plan” has the meaning set forth in Section 5.14 of the Purchase Agreements.

       

      “Event of Default” has the meaning set forth in the Indenture as of the date of the Purchase Agreements.

       

      
        30

        
          

      

      “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

       

      “Exchange Act Documents” has the meaning set forth in Section 5.4 of the Purchase Agreements.

       

      “FCPA” means the U.S. Foreign Corrupt Practices Act of 1977, as amended.

       

      “FDA” means the U.S. Food and Drug Administration or any successor thereto.

       

      “GAAP” means generally accepted accounting principles in effect in the United States from time to time.

       

      “Global Security” has the meaning set forth in Appendix A to the Indenture as of the date of the Purchase Agreements.

       

      “Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority,
        instrumentality, regulatory body, court, arbitrator, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national
        bodies such as the European Union or the European Central Bank).

       

      “Hazardous Substances” means (a) petroleum and petroleum products, by-products or breakdown products, radioactive materials, asbestos-containing materials, polychlorinated biphenyls and mold
        and (b) any other chemical, material or substance defined as toxic or hazardous or as a pollutant, contaminant or waste or words of similar import, or regulated or that can form the basis for liability, under Environmental Laws.

       

      “Immaterial Subsidiaries” has the meaning set forth in the Indenture as of the date of the Purchase Agreements.

       

      “Indenture” means that certain indenture for the Notes, dated as of July 15, 2019, as amended by that certain first supplemental indenture, dated as of the Closing Date, by and among the
        Issuer, the other subsidiary parties from time to time party thereto, the Trustee and the Collateral Agent.

       

      “Intellectual Property” has the meaning set forth in Section 5.21(a) of the Purchase Agreements.

       

      “IRS” means the U.S. Internal Revenue Service.

       

      “Issuer” has the meaning set forth in the preamble to the Purchase Agreements.

       

      “Laws” means, collectively, all applicable international, foreign, federal, state and local laws, statutes, treaties, rules, regulations, ordinances, judgments, orders, writs, injunctions,
        decrees, codes and administrative or judicial precedents or authorities, including the binding and enforceable interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration
        thereof, and all applicable administrative orders, directed duties, licenses, authorizations and permits of, and binding and enforceable agreements with, any Governmental Authority.

       

      
        31

        
          

      

       “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or
        otherwise perfected under applicable Law (including any conditional sale or other title retention agreement, any lease in the nature thereof, any option or other agreement to sell or give a security interest in and any filing of or agreement to
        give any financing statement under the UCC (or equivalent Laws) of any jurisdiction); provided, that in no event shall an operating lease be deemed to constitute a Lien.

       

      “Material Adverse Effect” means a material adverse effect (a) in or affecting the business, condition (financial or otherwise), results of operations, earnings, properties or prospects of
        the Issuer and its Subsidiaries taken as a whole or (b) on the ability of the Issuer to perform its obligations under the Transaction Documents.

       

      “Material Contract” means a contract or other agreement that is required to be filed by the Issuer with the Commission pursuant to Item 601(b)(4), Item 601(b)(10) or Item 601(b)(99) of
        Regulation S-K as an exhibit to the Exchange Act Documents.

       

       “Notes Collateral” means all property subject, or purported to be subject from time to time, to a Lien under any Security Documents.

       

      “Other Agreements” has the meaning set forth in Section 3.1(b) of the Purchase Agreements.

       

      “Other Purchasers” has the meaning set forth in Section 3.1(b) of the Purchase Agreements.

       

      “Patents” means (i) an issued patent or a patent application, (ii) all registrations and recordings thereof, (iii) all continuations and continuations-in-part to an issued patent or patent
        application, (iv) all divisions, patents of addition, reissues, renewals and extensions of any patent, patent application, continuation or continuation-in-part and (v) all counterparts of any of the above in any jurisdiction.

       

      “Paying Agent” means an office or agency where Notes may be presented for payment, maintained by the Issuer in accordance with Section 2.04(a) of the Indenture.

       

      “Permits” has the meaning set forth in Section 5.30 of the Purchase Agreements.

       

      “Permitted Lien” has the meaning set forth in the Indenture as of the date of the Purchase Agreements.

       

      “Person” means an individual, corporation, partnership, association, limited liability company, unincorporated organization, trust, joint stock company or joint venture, a Governmental
        Authority or any other entity.

       

      “Plan Assets” has the meaning given to such term by Section 3(42) of ERISA and regulations issued by the U.S. Department of Labor.

       

      
        32

        
          

      

      “PTE” means the United States Department of Labor Prohibited Transaction Exemption.

       

      “PTO” means the U.S. Patent and Trademark Office or any successor thereto.

       

      “Purchase Agreement” means this purchase agreement.

       

      “Purchase Agreements” means, collectively, each Purchase Agreement and the Other Agreements.

       

      “Purchaser” has the meaning set forth in Section 1.1 of the Purchase Agreements.

       

      “Purchasers” has the meaning set forth in Section 1.1 of the Purchase Agreements.

       

      “QIB” means a qualified institutional buyer within the meaning of Rule 144A.

       

      “QPAM Exemption” means PTE 84-14 (issued December 21, 1982, as subsequently amended).

       

      “Regulation S” means Regulation S under the Securities Act.

       

      “Regulation S Global Security” has the meaning set forth in Appendix A to the Indenture as of the date of the Purchase Agreements.

       

      “Regulatory Agencies” has the meaning set forth in Section 5.31 of the Purchase Agreements.

       

      “Responsible Officer” means, with respect to the Issuer, any director or officer of the Issuer.

       

      “Rule 144A” means Rule 144A under the Securities Act.

       

      “Rule 144A Global Security” has the meaning set forth in Appendix A to the Indenture as of the date of the Purchase Agreements.

       

      “Sanctioned Country” has the meaning set forth in Section 5.27 of the Purchase Agreements.

       

      “Sanctions” has the meaning set forth in Section 5.27 of the Purchase Agreements.

       

      “Securities Act” means the U.S. Securities Act of 1933, as amended.

       

      “Security Documents” means the security agreements, pledge agreements, mortgages, collateral assignments and related agreements, as amended, supplemented, restated, renewed, refunded,
        replaced, restructured, repaid, refinanced or otherwise modified from time to time, creating, perfecting or otherwise evidencing the security interests in the Notes Collateral as contemplated by the Indenture.

       

      “Similar Law” has the meaning set forth in Section 4.3(b) of the Purchase Agreements.

       

      
        33

        
          

      

      “Source” has the meaning set forth in Section 4.3(a) of the Purchase Agreements.

       

      “Subsidiary” means, with respect to any Person, (a) any corporation, association or other business entity (other than a partnership, joint venture or limited liability company) of which more
        than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time of determination owned or controlled,
        directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a combination thereof, and (b) any partnership, joint venture or limited liability company of which (x) more than 50% of the capital accounts,
        distribution rights, total equity and voting interests or general and limited partnership interests, as applicable, are owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a
        combination thereof, whether in the form of membership, general, special or limited partnership interests or otherwise, or (y) such Person or any Subsidiary of such Person is a controlling general partner or otherwise controls such entity. For
        purposes of clarity, a Subsidiary of a Person shall not include any Person that is under common control with the first Person solely by virtue of having directors, managers or trustees in common and shall not include any Person that is solely under
        common control with the first Person (i.e., a sister company with a common parent).

       

      “Sunovion License Agreement” means that certain License Agreement, dated as of April 1, 2016, by and between the Issuer (formerly MonoSol Rx, LLC) and Sunovion Pharmaceuticals Inc., a
        Delaware corporation (formerly Cynapsus Therapeutics Inc.), as amended from time to time in accordance with the terms thereof.

       

      “Supplemental Indenture” means that certain First Supplemental Indenture to the Indenture, dated on or after the date hereof, by and among the Issuer, the other subsidiary parties from time
        to time party thereto, the Trustee and the Collateral Agent, substantially in the form attached hereto as Exhibit B.

       

      “Taxes” means any present or future tax, fee, duty, levy, tariff, impost, assessment or other charge imposed by a Governmental Authority (including penalties, interest and additions to tax
        applicable thereto).

       

      “Transaction Documents” means the Indenture, the Notes, the Warrants, the Security Documents, the Purchase Agreements, any intercreditor agreement in the form of Exhibit D to the
        Indenture, and each other agreement pursuant to which the Collateral Agent (or its agent) is granted a Lien to secure the obligations under the Indenture or the Notes.

       

      “Trustee” means U.S. Bank National Association, as trustee under the Indenture.

       

      “Trustee Closing Account” means the account maintained with the Trustee at U.S. Bank National Association, ABA No. 091000022, Account No. 1731 0332 1092, Ref. Aquestive Senior Secured Notes,
        Attention: Alison D.B. Nadeau.

       

      “UCC” means the Uniform Commercial Code as in effect in the State of New York; provided, that, if perfection, the effect of perfection or non-perfection or the priority of any
        security interest in any Notes Collateral is governed by the Uniform Commercial Code (or equivalent Law) as in effect in a jurisdiction other than the State of New York, then “UCC” means the Uniform Commercial Code (or equivalent Law) as in
        effect from time to time in such other jurisdiction for purposes of the provisions relating to such perfection, effect of perfection or non-perfection or priority.

       

      “U.S.” or “United States” means the United States of America, its 50 states, each territory thereof and the District of Columbia.

       

      
        34

        
          

      

      Exhibit A

       

      Holder Consent

       

      (see attached)

       

      
        35

        
          

      

      Exhibit B

       

      Supplemental Indenture

       

      (see attached)

       

       

      

       36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]